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1. AIM OF THE STUDY 
This study addresses the question whether the microencapsulation of oils 
enriched with omega-3 fatty acids influences their stability when incorporated 
into foods. 
A search on the keyword “omega-3” in the web portal www.sciencedirect.com 
yields the astonishing number of 424,937 papers. There exists a huge amount 
of literature on analysis techniques on omega-3, the rigorous determination of 
all the chemical and/or enzymatic ways of their degradation, even the 
identification of precise decomposition products of omega-3 (and other 
unsaturated fatty acids present in oils enriched with omega-3). 
However, the literature is scarce in assessing the chemical stability of omega-3 
when incorporated into foods, and even more limited when the omega-3 are 
microencapsulated. What seems to be a straightforward evaluation, i.e. analysis 
of pure oils, turns to be extremely complicated due to the complexity of the food 
matrices and the non-validity of conventional analysis methods for omega-3 oils 
in foods as microcapsules. Further, the few accumulated experience remains 
secret to the public due to the industrial nature of such kind of research. 
One of the major commercial problems of this kind of functional foods is the 
development of fishy taste and smell over time. Apparently, the molecules 
responsible for this effect have been extensively characterized in controlled 
experiments, mainly with pure oils. However, the reality is that such chemical 
characterization has not been proven to be effective when omega-3 oils are 
incorporated in foods at the concentrations usually used in the food industry. 
Secondary oxidation products of omega-3 (i.e., peroxides’ decomposition 
products) provoke (at least partially) the undesirable fishy smell and taste. 
However, the well-established tests to determine the oil quality (this study being 
focused on fish oil) as peroxide value, acid value, p-anisidine value, 2-
thiobarbituric acid value, levels of conjugated dienes are of limited value in the 
assessment of the quality of foods enriched with omega-3 from fish oil (notably, 
these methods fail most of the time as well as definitive method of evaluation of 
omega-3 of microbial or vegetable origin). For example, C. Jacobsen found no 
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correlation between the organoleptic properties of mayonnaise enriched with 
omega-3 and the peroxide values; the undesirable smell and taste was only 
possible to be determined with panel testing [JACOBSEN, 1999]. Even 
Macfarlane et al. goes beyond the findings of Jacobsen: they showed that none 
of all the parameters abovementioned correlated with a trained taste panel 
response [MACFARLANE et al, 2001]. The experience at industrial level at GAT 
Food Essentials GmbH is coincident with Jacobsen and Macfarlane et al.  
 
It is therefore the aim of this study to try to fill this essential gap in the current 
knowledge on functional foods enriched with microencapsulated omega-3, 
namely, the correct evaluation of their chemical stability and their corresponding 
organoleptic characteristics in functional foods in comparison to the use of non-
microencapsulated omega-3. 
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2. FATTY ACIDS 
Chemically a fatty acid is a carboxylic acid with an aliphatic tail consisting of at 
least 4 in dairy fat to 30 carbon atoms in some marine lipids. The most 
important fatty acids in human nutrition are straight chained and contain an 
even number of carbon atoms (as explained later the preference of an even 
number is due to the predominant route of biosynthesis in plants and animals). 
Dietary fat comprises of tocopherols, cholesterol, phytosterols, fatty acids and 
many other substances. The chemical compounds in which fatty acids are 
mainly present in the diet are the triglycerides, which consist of approximately 
95% of fatty acids. This is due to the fact that in plants and animals fatty acids 
are present in the form of triglycerides in storage tissues because of their 
relative chemical inactivity. Monoglycerides and diglycerides, together with free 
fatty acids, contribute as well to the dietary fat. 
Whether in the form of mono-, di- or triglycerides, the metabolic route they 
follow in the human body results in the saponification catalysed by lipases of 
such glycerides to free fatty acids. Conversely, the fatty acids in the human 
body may be present in its free acid form, in the form of glycerides, as 
phospholipids, glycolipids or sphingolipids. In the body fatty acids are present in 
biological membranes, in fats deposits and blood lipids. 
Hereinafter, any reference to fatty acids shall be understood to include as well 
their other chemical forms in which they are present. Unless explicitly 
mentioned, data is interpreted towards biological systems. 
 
2.1 Nomenclature and structure of fatty acids 
2.1.1 Nomenclature 
For the nomenclature of fatty acids different systems are used. The international 
standard is that of the IUPAC (International Union of Pure and Applied 
Chemistry). The basis for the systematic nomenclature of fatty acids is the 
number of carbon atoms. Also the number and position of double bonds relative 
to the carboxyl group is referred. The carbon atom of the carboxyl group is 
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considered as number 1. The double bonds are identified by the lower number 
of the joined carbon atoms. So the correct IUPAC name for i.e. α-linolenic acid 
(ALA) is cis-9,cis-12,cis-15-octadecatrienoic acid. [IUPAC – IUB Commission on 
Biochemical Nomenclature, 1978] 
The IUPAC nomenclature system is sometimes replaced by a more 
straightforward nomenclature. Therefore for most naturally occurring fatty acids 
“trivial” or historical names, i.e. α-linolenic acid and shorthand notations are 
frequently in use. Shorthand notations adopt the form of carbon atom to double 
bond (C:D, i.e. ALA 18:3). 
Nutritionists and biochemists also often use the “n minus” or the “omega” 
system for naturally occurring cis-unsaturated fatty acids. This system refers to 
the double bond closest to the methyl end of the carbon chain (i.e. ALA 18:3 n-3 
or 18:3 ω-3). So this system starts counting on the non-carboxylic end of the 
molecule when compared with the IUPAC nomenclature. It is only the first 
double bond mentioned and also the configuration of the double bond is not 
mentioned. This system is not in use for trans-configurated fatty acids. 
Another system is the delta (Δ) system which numbers the carbon atoms with 
the beginning at the carboxyl group and also shows the configuration of the 
double bond (i.e. ALA 18:3 Δ9c,12c,15c). [RATANYAKE, 2009] 
 
2.1.2 Structure 
2.1.2.1 Saturated fatty acids (SFAs) 
Saturated fatty acids contain no carbon-carbon double bonds and have an 
unbranched structure. They mainly occur with chains from 4 – 24 carbon atoms 
and can be divided into subclasses. 
 Short-chain fatty acids 
Fatty acids with 4 to 6 carbon atoms are called short-chain fatty acids. The 
most important are butyric acid (C4:0) and caproic acid (C6:0), which occur in 
milk fat. They are usually not found in vegetable oils. 
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 Medium-chain fatty acids 
These are the fatty acids with a chain length from 8 to 12 carbon atoms. They 
occur in milk fats and vegetable oils. For example lauric acid (C12:0) is 
present in coconut and palm kernel oil.  
 Long-chain fatty acids 
Long-chain fatty acids cover the fatty acids with 14 – 20 carbon atoms. The 
most important are palmitic acid (C16:0) and stearic acid (C18:0). Palmitic 
acid occurs in more or less every fat. Stearic acid is present in most 
vegetable fats but is significant only in cocoa butter and shea butter. It also 
occurs in most animal fats and is a major component of tallow of ruminants. 
 Very-long-chain fatty acids 
These are all fatty acids with 22 or more carbon atoms. Fatty acids with 22 
and 24 carbon atoms occur in small amounts in most dietary fats. 
 
 
palmitic acid   C16:0    hexadecanoic acid 
 
stearic acid   C18:0    octadecanoic acid 
Figure 1: Examples of saturated fatty acids 
 
SFAs are the least reactive and therefore the most stable fatty acids. The 
melting point increases with chain length. 
2.1.2.2 Monounsaturated fatty acids (MUFAs) 
In general they are even numbered and have 14 to 24 carbon atoms. The most 
common and most widely distributed MUFA is oleic acid (C18:1 9c; C18:1 ω9), 
wherein the double bond is at the Δ9 position. Another mentionable 
monounsaturated fatty acid is erucic acid (C22:1,13c; C22:1 ω9). It occurs in 
higher levels in plants in the family Brassicaceae like rape and mustard and 
therefore also in rapeseed oil and mustard seed oil. In newer varieties of rape it 
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is removed because it showed negative health effects in several animal models. 
MUFAs with more than 22 carbon atoms are rare in the human diet. 
 
 
oleic acid   C18:1 9c   cis-9-octadecenoic acid 
 
erucic acid   C22:1 13c   cis-13-docosenoic acid 
Figure 2: Examples of monounsaturated fatty acids 
 
MUFAs are chemically more reactive than SFAs because of their carbon-carbon 
double bond. The melting point decreases with increasing of double bonds. 
2.1.2.3 Omega-6 polyunsaturated fatty acids 
Polyunsaturated fatty acids (PUFAs) have at least more than one carbon-
carbon double bond. Omega-6 or n-6 PUFAs show the first double bond on the 
sixth carbon atom counted from the methyl end of the carbon chain. Linoleic 
acid (LA) is the parent of the omega-6 fatty acids. It is present in almost every 
dietary fat and is the major component of some vegetable fats like sunflower 
and safflower oil. Due to its wide distribution many people over consume LA at 
the expense of the intake of omega-3 fatty acids. 
LA is essential for humans and can be desaturated and elongated to other 
omega-6 PUFAs (see Figure 3). The physiologically most important of these 
synthesised fatty acids are dihomo-gamma linolenic acid and arachidonic acid 
(AA). It is to mention that the conversion rate of LA to AA is only approximately 
10%. Arachidonic acid is also present in meat and egg lipids. 
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linoleic acid C18:2 9c,12c cis-9,cis-12-octadecadienoic acid 
 
arachidonic acid C20:4 5c,8c,11c,14c cis-5,cis-8,cis-11,cis-14-eicosatetraenoic acid 
Figure 3: Examples of omega-6 fatty acids 
 
2.1.2.4 Omega-3 polyunsaturated fatty acids 
Omega-3 PUFAs show their first double bond on the third carbon atom counted 
from the methyl end of the carbon chain. α-linolenic acid (ALA) is the parent of 
the omega-3 PUFAs. It is primary present in plants like in flaxseed oil in high 
amounts and also readily available in canola and soybean oil. From ALA the 
other omega-3 PUFAs like EPA, DPA and DHA can be formed through 
desaturation and elongation. Therefore the same enzyme systems as for the 
synthesis of the long chain omega-6 fatty acids are needed. 
Other very important omega-3 PUFAs are EPA (all cis-5,8,11,14,17-
eicosapentaenoic acid), DPA (all cis-4,7,10,13,16-docosapentaenoic acid) and 
DHA (all cis-4,7,10,13,16,19-docosahexaenoic acid). These are major 
components in marine lipids. Marine fish like mackerel, salmon, sardine, herring 
and smelt contain very high amounts of these long-chain PUFAs. Today also 
algal oils and single cell oils with considerable amounts of omega-3 PUFAs 
become available. 
The high importance of EPA and DHA is founded in their functions in the human 
body. EPA is the precursor for prostaglandins and thromboxanes, DHA is the 
precursor for docosanoids. DHA is also highly present in retinal cells, brain cells 
and cardiomyocytes, and very important for the brain development. 
ALA is, besides LA, the other essential FA for humans. 
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ALA C18:3 9c,12c,15c cis-9,cis-12,cis-15-octadecatrienoic acid 
 
EPA C20:5 5c,8c,11c,14c,17c all cis-5,8,11,14,17-eicosapentaenoic acid 
 
DHA C22:6 4c,7c,10c,13c,16c,19c all cis-4,7,10,13,16,19-docosahexaenoic acid 
Figure 4: Examples of omega-3 fatty acids 
2.1.2.5 Trans-fatty acids (TFAs) 
Most of the naturally occurring unsaturated fatty acids are cis-configurated, 
because the enzyme systems in plant and animal tissue for the elongation and 
desaturation of fatty acids are only capable of building cis-configurated 
unsaturated fatty acids. However there exist also trans-fatty acids in nature. 
Small amounts are enclosed in ruminant deposits and milk fats because they 
are produced from hydrogenation of unsaturated fatty acids through bacterial 
fermentation in the ruminant’s stomach. TFAs are also built through technical 
treatment as partial or hydrogenation of fats for blends for margarine, 
shortenings or deep fat frying. They can also be formed during the refining 
process of vegetable oils. 
The most important TFA is the trans-isomer of oleic acid. The double bond 
occurs between the positions Δ4 and Δ16. The most natural trans-18:1-fatty 
acid is vaccenic acid (C18:1 11t). 
Studies showed a positive correlation between the intake of trans-fatty acids 
and coronary heart disease. Trans-fatty acids also have a negative impact on 
the LDL/HDL ratio because they increase the levels of LDL and decrease the 
levels of HDL. [HUNTER, 2005; ELMADFA and LEITZMANN, 2004] 
Based on the outcome of these studies the EFSA (European Food Safety 
Authority) recommends that the intake of trans-fatty acids should be as low as 
possible. The FDA (U.S. Food and Drug Administration) issued a final rule 
requiring the mandatory declaration of the amount of trans-fatty acids on the 
nutritional label of foods and dietary supplements. The D-A-CH nutrition society 
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recommends that the amount of trans-fatty acids in the diet should be lower 
than 1% of the total energy intake per day, whereas neither the EFSA nor the 
FDA set an upper limit or a daily recommended value. The EU is currently 
working on a new legislation for nutrition labeling for foodstuffs which may be 
include also a mandatory declaration of fatty acids on the nutritional label of 
foods and dietary supplements. In Austria legislation already limits the content 
of trans-fatty acids up to 2% of the total fat content of foodstuffs. [FDA, 2003; 
MOSS, 2006; DGE, 2008; REPUBLIK ÖSTERREICH, 2009; EFSA, 2010] 
 
 
vaccenic acid C18:1 11t trans-11-octadecenoic acid 
Figure 5: Example of trans-configurated unsaturated fatty acids 
 
Exceptions are the isomers of conjugated linoleic acid (CLA). Discovered 
accidentally when searching for carcinogens from overcooked meat, the CLA 
isomers exhibited anti-carcinogenic instead of the prospected pro-carcinogenic 
properties. These properties could only be detected in cell lines. [PARIZA and 
HARGRAVE, 1985] 
CLA refers to a group of stereo- and positional isomers of linoleic acid (C18:2 
9c,12c). The predominantly positions for the double bonds are the carbon 
atoms 8 and 10, 9 and 11, 10 and 12, or 11 and 13. In the diet the most 
common is the cis-9,trans-12 isomer with more than 90%. Health benefits have 
been discovered through animal studies for mainly two of its isomers: cis-
9,trans-11- and trans-10,cis-12-octadecacienoic acid. [BHATTACHARYA et al, 
2006]
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conjugated linoleic acid C18:2 9c,11t cis-9,trans-11-octadecadienoic acid 
 
conjugated linoleic acid C18:2 10t,12c trans-10,cis-12-octadecadienoic acid 
Figure 6: Examples of CLAs 
 
The discovery of further benefits as body fat reduction, positive impact on 
insulin resistance, bone health and cardiovascular health in cell line and animal 
studies still need to be confirmed in human intervention trials. 
 
2.2 Biosynthesis of fatty acids 
2.2.1 Biosynthesis of saturated fatty acids 
The biosynthesis of fatty acids takes place in the cytosol of the cells of all 
organisms. In the beginning a molecule of acetyl-CoA is transformed to 
malonyl-CoA through carboxylation. Then fragments of 2 carbon atoms coming 
from the malonyl-CoA molecule are added to another molecule of acetyl-CoA. 
This reaction is catalysed through a multi enzyme complex, the fatty acid 
synthase. After the addition of acetyl-CoA and malonyl-CoA on the two SH-
groups condensation, reduction and dehydrogenation lead to a chain of carbon 
atoms. This reaction is carried out until the chain reaches a length of 16 carbon 
atoms. Then the acyl-compound is hydrolysed to palmitic acid (C16:0) and 
added to coenzyme A. Elongation further than to a chain length of 16 carbon 
atoms is carried out in the endoplasmic reticulum. [ELMADFA and LEITZMANN, 
2004] 
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Figure 7: Biosynthesis of saturated fatty acids [modified from LÖFFLER, 2002] 
 
2.2.2 Biosynthesis of unsaturated fatty acids 
Unsaturated fatty acids can be built via two different paths. The first possibility is 
the dehydrogenation of saturated fatty acids with the same chain length. The 
second path is an elongation of the carbon chain of medium-chain fatty acids. 
The dehydrogenation of stearic acid to oleic acid takes place in tissues of liver 
and muscle via the same enzyme complex which also converts palmitic acid to 
palmitoleic acid (C16:1 9c; C16:1 ω7) in the microsomes. Animal cells contain 
desaturases which only can add double bonds between the carboxyl group and 
the ninth carbon atom of the fatty acid. Therefore the fatty acids LA (omega-6) 
and ALA (omega-3) are essential. 
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2.2.3 Biosynthesis of polyunsaturated fatty acids 
The biosynthesis of PUFAs is divided into two reactions: first an elongation of 
the carbon chain from 16 carbon atoms to 22 carbon atoms is carried out. Then 
cis-configurated double bonds are built in the alkane chains. The elongation of 
the chain is localised in the membranes of the endoplasmic reticulum. The 
desaturation and the elongation proceed alternately. 
Linoleic acid (ω6) and α-linolenic acid (ω3) can’t be synthesised by the human 
or animal body because these organisms lack of the enzymes that are 
necessary for the addition of doube bonds between the ninth carbon atom and 
the methyl end of the fatty acid. The desaturation of linoleic acid to α-linolenic 
acid just occurs in the chloroplasts of marine algae and green leaves. 
Through elongation and desaturation of α-linolenic acid EPA and DHA can be 
built. For this animal organisms are also capable although this process is not 
efficient especially in infants. EPA and DHA accumulate in cold water fishes 
because they have a high intake through marine algae. 
Another problem which occurs when EPA and DHA are converted from ALA is 
the use of the same enzyme system which is needed for the conversion of LA to 
arachidonic acid. Due to the modern western diet the intake of LA is much 
higher than the intake of ALA. Therefore the enzymes like Δ6-desaturase, Δ6-
elongase and Δ5-desaturase are consumed for the conversion of omega-6 fatty 
acids instead of omega-3 fatty acids. The efficiency of the overall conversion of 
ALA is 0.2% to EPA and 0.05% to DHA (via EPA and DPA). One explanation 
may be the high amount of ALA which is β-oxidised to acetyl-CoA and used for 
the synthesis of cholesterol, SFA and MUFAs or metabolised to carbon dioxide 
(CO2). Because of these facts it might be better to increase the intake of EPA 
and DHA through the daily diet. [RATNAYAKE and GALLI, 2009; ELMADFA 
and LEITZMANN, 2004] 
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For the detailed description of the synthesis of EPA and DHA view  
Figure 8. 
 
Figure 8: Essential fatty acid metabolism in the human body: desaturation and elongation 
of omega-3 and omega-6 fatty acids [according to THORNE RESEARCH, INC., 2009] 
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2.3 Omega-3 fatty acids 
2.3.1 Physiological importance of omega-3 fatty acids 
2.3.1.1 Distribution of omega-3 fatty acids in the human body 
It is known that long-chain PUFAs are incorporated in cell membranes. They 
account for 21-36% of the fatty acids in these membranes. Especially to 
mention here is the distribution of fatty acids in the human brain. The human 
brain contains 50-60% of its dry weight as lipid and of these about 35% are 
PUFAs. But also the testis and the placenta are high in PUFAs. DHA is specific 
in its distribution in the different tissues. It is very abundant in the cell 
membranes of the brain, e.g. the gray matter, and of the retina especially in the 
rod photoreceptors. DHA is also high in phosphatidylserine and 
phosphatidylethanolamine of membranes in general and of course in 
synaptosomal membranes. [LAURITZEN et. al, 2001] 
Table 1 gives an overview of the distribution of omega-3 fatty acids in various 
tissues. 
Table 1: The fatty acids composition of various tissues for humans living in Western 
societies [according to LAURITZEN et.al, 2001] 
wt% of 
tissues 
fatty acids 
18:3 ω-3 20:5 ω-3 22:6 ω-3 
total 
PUFAs 
total 
LCPUFAs 
total ω-3 
adipose 
tissue 
0.8 traces 0.3 13.1 1.1 1.9 
red blood 
cells 
not 
detectable 
0.7 3.2 33.3 24.0 5.7 
placenta no data 0.1 4.8 44.4 34.2 6.3 
liver 0.3 0.4 3.4 32.0 14.2 4.6 
testis 0.7 no data 8.5 30.7 24.4 9.2 
brain 
cerebrum 
traces traces 7.2 23.4 22.8 7.4 
retina 
not 
detectable 
0.1 19.7 37.2 35.5 21.1 
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2.3.1.2 Dietary Requirements 
Absolute amounts of fat and individual fatty acids which are compulsory for 
human health and metabolic integrity cannot be determined because of 
insufficient data on this field of research. 
For omega-3 fatty acids some points are clear. ALA is an essential fatty acid 
because of its role as precursor for EPA and DHA. The mean ALA intakes for 
adults in the European population are not associated with any signs of 
deficiency (0.7 – 2.3 g/day; 0.4 – 0.8 E%). For infant formula the same amounts 
as delivered normally by human milk are requested (0.5 – 1.0 % of fat as 
omega-3 fatty acids). [EFSA, 2010] 
The conversion from ALA to EPA and DHA is very low. According Hussein et al. 
the estimated conversion from ALA to EPA and DHA combined is less than 
0.4% and the conversion from ALA to DHA is less than 0.1%. [HUSSEIN et al., 
2005] Other sources estimate the conversion to be about 0.2 % to EPA and 
0.05 % to DHA. [PAWLOWSKY et al., 2001] It is also known that the conversion 
rate is increased by estrogens so that women convert twice as much ALA to 
DHA than men. [BURDGE and WOOTTON, 2002] 
The requirements of pregnant women increase during the last trimester of 
pregnancy because of the accumulation to accommodate the needs of the 
infant for deposition of DHA in the brain and in the retina (about 10g) and also 
during six months of lactation (12 – 14g). Therefore they have an additional 
requirement of 90 – 100 mg/day over their basic DHA requirement. [SACN, 
2004] 
 
2.3.1.3 Serum lipids and lipoproteins 
EPA and DHA lower serum triacylglycerol concentrations compared to other 
fatty acids. This effect is also evident in patients with increased serum 
triacylglycerol levels. These fatty acids also slightly increase LDL and HDL 
cholesterol. The effects of fish oil fatty acids on the serum lipoprotein profile are 
small at daily intakes <1g/d. [BALK et al., 2006] 
There is also the effect of decreasing VLDL concentrations [HARRIS, 1997]. 
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Apparently the intake of omega-3 fatty acids from fish oil promotes a change in 
lipoprotein fatty acid composition. This may affect some physiological events 
associated with atherosclerosis. The benefits of EPA and DHA may be 
increased according to cellular events such as reductions in fibrinogen, platelet-
derived growth factor, platelet activating factor and increases in tissue 
plasminogen activator and endothelial-derived relaxation factor. [LAYNE et al., 
1996] 
There is also evidence that the plasma level of EPA increases by provision of its 
precursor ALA in form of flaxseed oil capsules. Harper et al. showed in their 
study a significant increase in EPA and DPA but not in DHA plasma lipids with a 
relatively low dose of ALA (3g/d), which can also be obtained through a 
reasonable diet containing ALA-rich nuts, cereals and oils. [HARPER et al, 
2006] 
 
2.3.1.4 Inflammation and immune function 
Prostaglandins, prostacyclins, thromboxanes and leukotrienes and hydroxyfatty 
acids converted out of the omega-6 fatty acids like arachidonic acid act pro-
inflammatory whereas prostaglandins, prostacyclins, thromboxanes and 
leukotrienes and hydroxyl fatty acids established out of omega-3 fatty acids like 
EPA and DHA act anti-inflammatory. 
EPA and DHA inhibit the pro-inflammatory interleukins, tumour necrosis factor α 
and the 2 series of inflammatory PGs when they are released by an injured cell 
membrane. Improvements in joint pain and function when suffering on chronic 
inflammatory conditions are reported after application of ω-3 fatty acids. 
[MAROON and BOST, 2006] 
As omega-3 fatty acids compete with omega-6 fatty acids for the same enzyme 
systems for conversion to eicosanoids like prostaglandins, thromboxanes and 
leukotrienes, a fish oil supplementation shows decreased production of omega-
6 related prostaglandins and thromboxanes by inflammatory cells and increased 
production of the omega-3 related anti-inflammatory eicosanoids. Long chain 
omega-3 PUFAs also affect the cell surface expression of adhesion molecules 
which leads to a different reaction. [CALDER, 2006] 
17 
 
 
Figure 9: Conversion of eicosanoids [according to LUNN and THEOBALD, 2006] 
 
2.3.1.5 Cardiovascular disease 
CVD, including coronary heart disease (CHD), stroke and other diseases of the 
cardiovascular system, is one of the leading causes of mortality and morbidity 
worldwide. It is characterised by hardening and narrowing of the blood vessels, 
the atherosclerosis, as well as development of blood clots called thrombosis. 
There are various risk factors including the not modifiable like age, sex and 
ethnicity and the influenceable like smoking, physical inactivity, hypertension, 
abnormal blood lipids, obesity and diabetes. 
Unsaturated fatty acids reduce the risk of CVD but the precise mechanisms are 
not clear yet. 
According several studies including cohort studies [HU et al., 2002], and 
intervention trials with fish oil supplements [GISSI-Prevenzione Investigators, 
1999] there is supportive evidence that the LCPUFAs EPA and DHA protect 
against fatal heart disease. They also affect the platelet aggregation due to the 
pro-inflammatory 
anti-inflammatory 
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different eicosanoids synthesised out of EPA and AA. Therefore population-
wide recommendations have been established to support the intakes. It gets 
more and more obvious that ALA may play a role in preventing CVD. But it is 
not clear what association exists between CVD risk and ALA intake. [LUNN and 
THEOBALD, 2006] 
In clinical trials there was no evidence that an increased intake of fish beyond 
one or two servings per week is likely to improve the primary prevention of 
CVD. There was also no association found between the incidence of myocardial 
infarction and fish oil intake. [STONE, 1996] 
The GISSI-Prevenzione study showed that the supplementation of 1g omega-3 
fatty acids per day (this provides 850-882mg of EPA and DHA ethyl esters) 
reduced the primary end point, which was set as death, nonfatal myocardial 
infarction, and stroke, by 15% and the risk of death by any cause by 20% 
significantly. This trial was carried out for 3.5 years. Although the mechanisms 
of action and the optimum dosage for prevention are not yet clear omega-3 fatty 
acids should be considerate for life-prolonging therapies for cardiovascular 
diseases. [GISSI-Prevenzione Investigators, 1999] 
As the GISSI-Prevenzione study just showed a significant effect of omega-3 
fatty acids in secondary prevention, the GISSI-HF study also investigated the 
effect of omega-3 fatty acids in primary prevention. However, the treatment with 
EPA didn’t show a significant reduction in major coronary events. [GISSI-HF 
Investigators, 2008] 
Especially in primary prevention there is essential need for further research to 
clarify evidence for the preventive effect of omega-3 fatty acids. 
 
2.3.1.6 Cancer 
A recent study showed the effect of fish consumption and omega-3 fatty acid 
intake on breast cancer in pre- and post menopausal women in South Korea. 
According to their results the consumption of fatty fish correlates positive with a 
reduced risk of breast cancer. Also the intake of omega-3 fatty acids showed a 
reduction of postmenopausal breast cancer. [KIM et al., 2009] 
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Thiébaut et.al didn’t find a significant impact of a high intake of long-chain 
omega-3 PUFAs on the risk of breast cancer in their prospective cohort study. 
But there was evidence that an increased ratio omega-3 to omega-6 PUFAs 
can decrease the risk of breast cancer. This may be referred to the competition 
of omega-3 and omega-6 fatty acids in the formation of eicosanoids. 
[THIÉBAUT et al., 2009] 
They have also a positive influence on the expression of colon carcinomas. But 
there are large-scale studies needed to detect the mechanisms on which their 
anti-carcinogenic effects are based on. [KAPOOR, 2009 and CHAPKIN et al., 
2007] 
 
2.3.1.7 Retina development and function 
During late fetal development and shortly after birth omega-3 fatty acids 
accumulate in the retina, especially in the membranes of the photoreceptor 
cells. More than 50% of the fatty acids in the phospholipids of outer limiting 
membrane of the retina are represented by DHA. [STONE et al., 1979] 
A lack of DHA is related with impaired visual function, such as the acuity of 
vision, because DHA is known to be a fundamental component of the 
membrane-linked phosphoglycerides of the retina. [BIRCH et al., 1993 and 
BIRCH et al., 1998] 
DHA may has an influence on the photochemical activity of rhodopsine. 
Therefore it is determining the threshold of the light perception and activates 
chemical reactions, which are responsible for activation of nerve impulses. 
[HAHN et al., 2002] 
 
2.3.1.8 Brain development and function 
A characteristic feature of the mammalian brain to mention is the high 
concentrations of DHA in the ethanolamine phosphoglycerides (EPG) and 
phosphatidylserine (PS). This is even shown among herbivores although they 
have low concentrations of DHA in plasma and hepatic lipids. There is also 
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strong evidence that the brain has the ability to concentrate DHA, may localised 
in the capillary endothelium, which contains high amounts of DHA. 
Functions of lipid-bound DHA in the membrane include properties of the 
hydrophobic membrane core, like a high flexibility and direct interaction with 
membrane proteins, which impact signal transduction, neurotransmission and 
formation of lipid rafts. Unesterified DHA can be metabolised to neuroprotective 
metabolites and have a role in regulating gene expression, like the inhibition of 
oxidative stress-induced induction of proinflammatory genes and apoptosis in 
the brain and the retina. [INNIS, 2007] 
Birberg-Thornberg et al. showed a positive correlation between DHA in 
maternal milk and the development of the ability to represent mental states like 
beliefs and intentions referred to as the Theory of mind (ToM). The value of the 
study is limited due to the small number of participants but correlate with 
previous findings according to omega-3 LCPUFAs and the intelligence of 
children. [BIRBERG-THORNBERG, 2006] 
Broadhurst et al. found evidence that the preparation of LCPUFAs for the early 
human and therefore could have supported a rapid cerebral cortex enlargement 
without an enormous increase in body mass. So it is postulated that a diet 
chronically-low in LCPUFAs will lead to suboptimal brain development. There is 
evidence today that a lack of DHA in utero and also in infant nutrition results in 
a lower intelligence and also in depression and attention-deficit hyperactivity 
disorder in later years. [BROADHURST, 1998] 
However, the development of intelligence is a field which needs much more 
studies not only in association with omega-3 PUFAs. 
 
2.3.1.9 Mental Health 
With omega-3 fatty acids a new family of therapeutic substances for the 
psychiatrics emerged. They have to be seen as alternative or addition to 
present applied possibilities like antidepressants. Many studies show a negative 
correlation between the intake of fish oil or omega-3 fatty acids and the 
depression score. [EDWARDS et al., 1998] 
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Also a low amount of omega-3 fatty acids in serum and in the erythrocytes of 
patients with major depressions was measured. [MAES et al., 1996 and 
EDWARDS et al., 1998] 
Low fish and DHA consumption is fairly linked with the risk of Alzheimer’s 
disease. Also lower blood levels of DHA are contributed to a higher risk of 
cognitive decline and Alzheimer’s disease. But more research is definitely 
needed. The focus should be how DHA is biologically linked to Alzheimer’s 
disease. This knowledge is necessary to find a useful role for DHA as nutritional 
supplements for protecting against some forms of dementia. It is also not clear if 
DHA has just a role in prevention of Alzheimer’s disease or could be used to 
treat it. [CUNNANE et al., 2009] 
Patients with the attention deficit disorder show lower plasma levels of EPA and 
DHA. To treat this disorder the patients usually have to take substances which 
increase the neurotransmitter dopamine in the brain. Omega-3 fatty acids may 
have the same effect. [ANTALIS et al., 2006] 
According to a recent meta-analysis there is good evidence that DHA is 
neuroprotective via many different mechanisms. It reduces arachidonic acid and 
its metabolites like the prostaglandins. DHA also increases activity of 
antioxidative enzymes like catalase and GSH peroxidase and improves the 
synaptic membrane fluidity. Compared to many new medications DHA has 
outstanding benefits like long-term safety, minimal side effects and relative low 
costs. [COLE et al., 2009] 
 
2.3.1.10 Foetal and infant development 
An adequate supply of long chain omega-3 PUFAs before and throughout 
pregnancy is very important to support neurological development and cognitive 
function of the growing fetus. [LUNN and THEOBALD, 2006] 
Before birth placental transfer provides all the required omega-3 fatty acids. 
Therefore the plasma level of DHA, although higher in the foetus than in the 
mother, is influenced by the maternal diet. The placental fatty acid transfer is 
dependent on maternal fatty acids, but is not regulated to protect the foetus 
from low maternal DHA. [INNIS, 2008] 
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DHA and other omega-3 fatty acids vary widely in human milk according to 
differences in the maternal diet. Vegan and vegetarian diets lead to very low 
concentrations of DHA. Increasing the maternal DHA intake can increase the 
amount of DHA in the human milk. [INNIS, 2008] 
 
2.3.1.11 Body weight and energy balance 
For the effect of omega-3 fatty acids on the body weight and energy balance the 
results of different studies vary widely. According to Couet et al. omega-3 fatty 
acids from fish oil have the ability to reduce the body fat mass of healthy adults 
significantly and also increase the fat-free calcium-free mass. The resting 
metabolic rate increased also in this study during fish oil supplementation. They 
recommend a daily intake of 6 g fish oil per day to gain these results. [COUET 
et al., 1997] 
Kratz et al. showed in their study the contrary. In their study with overweight 
adults the increased dietary omega-3 content to 3.6% of total energy didn’t have 
any effect on the body weight or fat mass. [KRATZ et al., 2009] 
 
2.3.2 Sources of omega-3 fatty acids 
2.3.2.1 Natural Sources 
ALA is present in vegetable oils like flaxseed oil and in some green vegetables 
like broccoli. For long chain omega-3 PUFAs fish and fish oils are the main 
source in the human diet. But in these the LCPUFA also come originally from 
plant sources, such as phytoplankton like Schizochytrium sp. Now also the 
fermentation of microalgae and algae-like microorganisms are considered as 
new sources of omega-3 PUFAs. 
Detailed contents of the different PUFAs in foods are shown in Table 2. 
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Table 2: Omega-3 PUFA contents of different natural sources [according to LI et al, 2003] 
 
content 
fish [mg/100mg edible flesh] ALA EPA DPA DHA total 
golden bream 3 43 34 168 247 
sea mullet 120 1318 635 286 2359 
atlantic salmon 80 472 439 1147 2138 
cultivated rainbow trout 35 53 26 442 556 
southern bluefin tuna 3 230 115 804 1152 
lean meat [mg/100g product] ALA EPA DPA DHA total 
beef 16 ± 2 16 ± 2 23 ± 4 3 ± 1 58 ± 9 
pork 8 ± 2 3 ± 1 7 ± 1 3 ± 1 21 ± 4 
chicken 16 ± 8 4 ± 0 8 ± 2 6 ± 2 34 ± 11 
lamb 65 ± 18 23 ± 4 22 ± 1 8 ± 2 118 ± 2 
vegetables [mg/100g fresh 
product] 
ALA EPA DPA DHA total 
broccoli 110 ± 16 - - - 114 ± 17 
spinach 129 ± 16 - - - 150 ± 19 
watercress 180 ± 71 - - - 225 ± 83 
vegetable oils [mg/100g oil] ALA EPA DPA DHA total 
flaxseed oil 60000 - - - - 
olive oil 600 - - - - 
safflower oil 400 - - - - 
Further it is to mention that the modern Western diets show an imbalance 
between omega-3 and omega-6 fatty acids. This is a result of the modern 
agribusiness, the modern agriculture with the high consumption of vegetable 
oils containing high amounts of omega-6 fatty acids, and the modern 
aquaculture which also leads to a decrease of omega-3 fatty acids in cultivated 
fish compared to wild fish. [GUNSTONE, 2007; SIMOPOULOS, 1999] 
The balance of omega-6 and omega-3 fatty acids is very important for 
homeostasis and normal development. The ratio should at least be 5:1 to 
ensure an appropriate intake of both. [DGE, 2008] 
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2.3.2.2 Fortification 
Fortification of food products is based on the proposed effect of the biologically 
active ingredient. On the European market there are many products that are 
enriched with omega-3 fatty acids. The range reaches from margarine to milk 
and from juices and shots to cookies and bread. Mostly the products contain 
amounts that ensure that the adequate intake of omega-3 fatty acids could be 
reached with one serving of the product. Mostly the products are not only 
enriched with plain fish oil but with stabilised fish oil e.g. by microencapsulation. 
In 2009 the sales of omega-3 products grew 42% despite of the recession 
[WILLIAM REED BUSINESS MEDIAS, 2010]. One reason for this is, amongst 
others, the consumer’s increasing interest in healthy diet. The largest part of the 
market is accounted by fortificated dairy products. 
 
2.3.2.3 Supplements 
Fish oil supplements rich in omega-3 polyunsaturated fatty acids are widely 
used because most people do not reach the adequate intake of 250mg EPA & 
DHA per day [EFSA, 2010]. They often deliver high dosages of omega-3 
PUFAs, sometimes twice as high as the recommended intake values. 
Sometimes they also can cause negative side effects such as “fish burps” or 
gastro-intestinal problems like diarrhea. So although they can help you to 
achieve the adequate intake value, a natural source is always the better 
decision because also the bioavailability can be lower in supplements than in 
real food. [KRIS-ETHERTON and HILL, 2008) 
 
 2.3.3 Average fat intake in Austria 
The average fat intake of adults in Austria is with 36-38% of the total energy 
intake too high. For children the fat intake is within in the range of the 
recommendations (30-35% of the total energy intake). For the polyunsaturated 
fatty acids the intake is for children a little less than recommended, for adults 
the intake is appropriate. [ELMADFA et al, 2009] 
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Table 3: Intake of fat and fatty acids among children and adults in Austria [according to 
ELMADFA et al, 2009] 
  
Fat total, 
E% 
PUFA, 
E% 
ALA, 
g/day 
ALA, 
E% 
EPA, 
g/day 
EPA, 
E% 
DHA, 
g/day 
DHA, 
E% 
Men 
18-65years 
37 8 1.50 0.50 0.08 0.03 0.20 0.07 
Women 
18-65 years 
37 8 1.30 0.60 0.07 0.03 0.20 0.09 
Boys 
7-10 years 
34 6 0.80 0.40 0.02 NA 0.07 NA 
Girls 
7-10 years 
34 6 0.70 0.40 0.02 NA 0.07 NA 
Boys 
11-14 years 
34 6 1.20 0.60 0.03 NA 0.10 NA 
Girls 
11-14 years 
34 6 1.00 0.50 0.03 NA 0.09 NA 
 
2.3.4 Recommendations for the fat intake 
2.3.4.1 D-A-CH 
The nutrition societies of Germany, Austria and Switzerland have created 
together reference values for the nutrient intake. For fat in general they 
published a guideline referring to a fat intake lower or equal to 30% of the daily 
total energy intake. 
For PUFAs, especially for EPA and DHA, the nutrition societies set an 
estimated value of 250 mg EPA+DHA per day to achieve the promised 
prevention against coronary heart disease. For pregnant and breast-feeding 
women an advice of an intake of 200 mg DHA per day is given to ensure an 
optimal development of the nervous system of the foetus. [DGE, 2008] 
2.3.4.2 WHO/FAO 
The joint experts of FAO/WHO set an acceptable macronutrient distribution 
range for adults with 20-35% fat intake of the total energy intake. For infants an 
adequate intake of 35-60% fat intake of the total energy intake. 
For omega-3 PUFAs a range is given with 250 mg – 2 g per day. The higher 
value refers to secondary prevention of CHD. For infants (0-24months) an 
adequate intake of 10-12 mg DHA per kg body weight is recommended. For 
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children from 2 years to 10 years the values for an adequate intake of EPA & 
DHA are bridged from the infant value to the adult value with 100-150 mg per 
day to 200-250 mg per day. There is no need of a special ratio of ω-6 to ω-3 
fatty acids as long the intake is within the recommendations. [WHO/FAO, 2008] 
2.3.4.3 EFSA 
The EFSA Panel set a recommended daily intake for adults of 20-35% fat of the 
total energy intake. For children up to 3 years they recommended 35-40% fat of 
the total energy intake. 
For omega-3 PUFAs they don’t set a daily reference value, but for EPA & DHA 
an adequate intake of 250 mg per day is important for adults. For children up to 
1 year the intake should exceed 100 mg DHA per day. [EFSA, 2010] 
In the recent months the EFSA panel published the first opinions on submitted 
health claims referring to general health functions of omega-3 fatty acids. So far 
the EFSA panel published positive opinions on claims referring to the influence 
of omega-3 fatty acids on blood pressure and blood lipids. The European 
Commission already published a health claim referring to children’s health. 
[EFSA, 2009; EUROPEAN COMMISSION, 2009] 
 
2.4 Stability of polyunsaturated fatty acids 
The most important impact on the stability of polyunsaturated fish oil is lipid 
peroxidation. Due to their high amount of unsaturated carbon atoms the 
probability of oxidation is very high. 
Figure 10 shows the schematic reaction of lipid peroxidation. In the beginning a 
hydrogen radical is separated from an unsaturated fatty acid. This leads to an 
unstable carbon radical. Molecular rearrangement occurs and this causes a 
conjugated diene. Then the carbon radical reacts with oxygen and a peroxyl 
radical is formed. Formerly built radicals react with the peroxyl radical and a 
lipid peroxide is formed. As there are always new radicals formed throughout 
this reaction a chain reaction is the consequence which affects more fatty acids 
in each reaction step. Therefore the number of peroxides increases 
exponentially. 
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Some of the end products as 4-hydroxynonenal are responsible for the bad 
taste and smell rancid oils develop. 
 
 
Figure 10: Schematic reaction lipid peroxidation [according to EBERMANN and 
ELMADFA, 2008] 
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Many studies have examined the stability and shelf life of plain fish oil. To show 
an example of such studies the study of Boran et al. is taken. In this study the 
oils of horse mackerel, shad, garfish and golden mullet were tested for their 
ester value (EV), acid value (AV), iodine value (IV), peroxide value (PV) and 
saponification value (SV) during 150 days storage at 4°C and -18°C. These fish 
are common for the Turkish market and contain all high amounts of 
polyunsaturated fatty acids. After the storage time garfish and shad show the 
greatest stability against oxidation and preserved their properties at -18°C for 
the whole storage period. Generally they showed said that the fish oils’ shelf life 
was twice as long when they were stored at -18°C than at 4°C. [BORAN et al, 
2006] 
In the study of Let et al. the influence of fish oil quality on the oxidative stability 
of milk enriched with pure fish oil or a fish oil-rapeseed oil mixture was 
evaluated. This study shows that the storage temperature has important effects 
on the oxidation of the fish oil enriched milk emulsions. Best results were gained 
with the mixture of fish oil and rapeseed oil. [LET et al, 2005] 
A study from Skall Nielsen et al. showed a very good stability of fish oil in 
drinking yoghurt. There was no oxidative instability observed in drinking yoghurt 
enriched with 2.0 % fish oil after more than 2 weeks storage at 2 °C. Also the 
sensory evaluation showed no fishy off-flavour during the storage time. These 
results may be attributed to the low pH of the yoghurt. [SKALL NIELSEN et al, 
2007] 
Serfert et al. showed that microencapsulation by spray drying can stabilise fish 
oil but it has to be considered that this multiphase system has very 
heterogeneous characteristics. The stability can also be influenced by oxidation 
that may occur already during the spray drying process. This can lead to high 
values of peroxides and hydroperoxides and therefore to a decrease of storage 
stability. [SERFERT et al, 2009] 
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2.5 Analysis of polyunsaturated fatty acids 
2.5.1 Analysis by gas chromatography (GC) 
Analysis of fatty acids by as chromatography is the most common way of 
qualification and quantification of the fatty acid pattern of oils or other foods. It 
enables a complete analysis in a relatively short time. For the analysis by gas 
chromatography the fatty acids have to be converted into fatty acid methyl 
esters (FAME). This is carried out with a surplus of methanol and is either 
catalysed by sodium methoxide or borontrifluoride. Early methods included also 
diazomethane as catalyst. As stationary phase polar polyester or fused silica 
capillary columns are in use. As carrier gas helium is the choice because it is 
much safer than hydrogen and retention times do not change when the speed 
of the gas flow changes. 
Several detectors, like flame ionisation detector (FID), electron capture detector 
(ECD) or mass spectrometry (MS), can be used for the analysis of fatty acids, 
but in most studies the flame ionisation detector is used. GC/MS detection is 
often used for the analysis of trace amounts. [CHRISTIE, 2003; PETROVIĆ et 
al, 2010] 
 
2.5.2 Analysis of fatty acids by high performance liquid 
chromatography (HPLC) 
In recent years the advantages of HPLC in the analysis of fatty acids are 
recognised. It is widely used to analyze compounds which are highly volatile like 
decomposition products of polyunsaturated fatty acids. Separation modes can 
be divided into reversed phase (RP), which is commonly used for the separation 
of organic acids, hydroxyl-polyunsaturated fatty acids or other polar lipids, and 
normal phase (NP), which is used for the analysis of free fatty acids and other 
non-polar lipids. Both modes show no limitation for MS as detector. One 
advantage of HPLC compared with GC is the wide range of different derivates 
that can be used for analysis. The choice of derivatives depends on the detector 
that will be used., e.g. methylated derivatives for FID, UV-absorbent derivatives 
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for UV-VIS detector, fluorescent derivatives for fluorescence detector. Besides 
MS also UV-VIS detectors, fluorescence detectors or 1H NMR (nuclear 
magnetic resonance spectroscopy) can be used. 
Another form of HPLC which is used for separation and quantitation of cis/trans 
fatty acids or FAME positional isomers is silver ion chromatography (Ag+-
HPLC). [SAJIKI and YONEKUBO, 2002; RUIZ-RODRIGUES et al, 2010] 
 
2.5.3 Chemical constants 
Before modern analytical methods like gas chromatography or HPLC were 
developed many chemical constants were used for identification and 
determination of the composition and quality of fats and oils. Whereas most of 
these constants are not necessary anymore some of them are still used due to 
their information value and their simple use. [MATISSEK, STEINER, and 
FISCHER, 2010] 
2.5.3.1 Saponification value (SV) 
The SV is a measure for the bound and free fatty acids in a fat or oil and is 
linked to the average molecular weight of the fatty acids. The lower the average 
molecular weight the higher is the SV. The SV can be used for the 
determination of purity of certain fats and oils. 
Definition: The SV refers to the amount of KOH in mg, which is necessary for 
the saponification of 1 g fat. 
2.5.3.2 Iodine value (IV) 
The iodine value is a measure for the amount of unsaturation contained in a fat 
or oil. The higher the IV is the higher is the amount of double bonds in a fat. 
Therefore the IV can be used for determination of purity and identity of fats and 
oils. Besides the unsaturated fatty acids the unsaturated fat-accompanying 
substances are also detected. 
Definition: The IV refers to the amount of halogens in g, based on iodine, which 
is bound by 100 g of fat or fatty acids. 
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2.5.3.3 Acid value (AV) 
The acid value is a measure for the amount of free acids in fats, oils or fatty 
acids. Besides fatty acids also mineral acids can be detected. Acids linked to 
glycerol are not detected by this method. The AV is used as purity 
measurement and also refinement of oils can be detected by this method. 
Unrefined oils, such as virgin and cold pressed oils show an AV up to 10 
whereas refined oils usually have an AV lower than 0.2. 
Definition: The AV refers to the amount of KOH in mg, which is necessary for 
the neutralization of the free acids contained in 1 g fat oil or fatty acids. 
2.5.3.4 Peroxide value (PV) 
Hydroperoxide (ROOH) formation is one of the first steps of lipid oxidation. 
Peroxides are intermediate products and could lead to the formation of volatile 
compounds like hexanal, heptanal acetaldehyde. The hydroperoxides react with 
triplet or singlet oxygen. Triplet oxygen is a di-radical molecule that reacts 
directly with molecules in singlet state and as well with molecules in doublet-
state such as radicals. Singlet oxygen is a non-radical and electrophilic 
molecule and can react directly with electron-rich double bond containing 
compounds like oleic acid, LA or ALA. 
The formation of hydroperoxides is an autocatalytic reaction, which means that 
at least one of the products is also a reactant. The hydroperoxides are 
decomposed to low molecular weight volatile compounds, e.g. aldehydes, 
ketones, alcohols, acids and hydrocarbons. The aldehydes are responsible for 
the rancid flavour of oxidised oils but there are approximately 150 volatile 
compounds built during oxidation of vegetable oils. [HAHM and MIN, 1995] 
The peroxide value is a measure for the peroxidic bond oxygen in fats or oils. 
Definition: The PV refers to the amount of active oxygen in 1 kg of sample. 
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2.5.4 UV-VIS Spectrophotometric analysis 
2.5.4.1 Conjugated dienes 
One of the first steps in the oxidation of linoleic acid or higher PUFAs is a 
shifting of double bonds. Pentadienyl radical is formed during oxidation. This is 
able to shift into two possible conjugated dienes (CD). These could react with 
molecular oxygen to hydroperoxides. The increase of double bond 
displacement correlates with the degree of peroxidation in an unsaturated oil. 
As these conjugated structures absorb strongly at wavelengths of 232 – 234 nm 
they can be measured easily. The CD value represents the percentage of 
conjugated dienoic acid in an unsaturated oil and is an indication of primary 
oxidation products. The CD value does not increase further when a certain 
concentration is reached.  
The amount of PUFAs in an oil and CD correlate positively. But the magnitude 
in the change of the CD cannot be related to degree of oxidation because this is 
highly influenced by the plant species and the fatty acid profile. [NOOR and 
AUGUSTIN, 1984] 
The CD value can be used as a relative measurement of oxidation in a 
particular oil with known fatty acid composition. [WHITE, 1995] 
2.5.4.2 Conjugated trienes 
Conjugated trienes (CT), which can be measured with the same system and 
sample preparation as CD at a wavelength of 268 nm, ethylenic diketones, 
conjugated ketodienes and dienals are secondary oxidation products. The CT 
value represents the percentage of conjugated trienoic acid in an unsaturated 
oil and is an indication of secondary oxidation products. [WHITE, 1995] 
 
2.5.5 Fluorometric analysis - ORAC assay 
The ORAC (oxygen radical absorbance capacity) assay is used to measure the 
antioxidative capacity of various materials such as essential oils, dietary 
supplements or spices. The basic assay bases upon the reaction of a peroxyl 
radical with a fluorescent probe and the formation of a nonfluorescent product. 
The peroxide radicals are formed by AAPH. The reaction is quantified by the 
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measurement of the change in fluorescence. The results are expressed as 
Trolox equivalents. Trolox is a water soluble vitamin E analog. 
The relevance of the antioxidative capacity gets widely accepted in the food 
industry. [BENTAYEB et al., 2009] 
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3. MICROENCAPSULATION TECHNOLOGY 
Microencapsulation is defined as ‘the technology of packaging solid, liquid and 
gaseous materials in small capsules that release their contents at controlled 
rates over prolonged periods of time’. [CHAMPAGNE and FUSTIER, 2007] 
Originally this technology was used for the pharmaceutical industry to stabilise 
sensitive active ingredients. But in recent years it gets more and more important 
for the food industry especially for the sector of functional foods. The addition of 
active ingredients to functional foods is often challenging because of the 
stability of these ingredients during production and storage of the final product. 
Another point is the matter of taste in the final product. The active compounds 
should not affect the desired or expected taste of the food. Microencapsulation 
is also useful for the controlled release of the nutrients in the gastrointestinal 
system. [CHAMPAGNE and FUSTIER, 2007] 
There are several techniques for microencapsulation of active ingredients 
especially of oils rich in omega-3 LCPUFAs. They are differentiated by the way 
of building up the carrier matrix surrounding the core material. 
 
 Microencapsulation by spray drying 
Spray drying is in use for microencapsulation of flavours and lipids for 
decades. The process is divided in 4 stages: (1) preparation of the emulsion 
to be processed, (2) homogenisation, (3) atomisation of the emulsion and 
(4) dehydration of the atomised particles. 
The core material is dispersed into a solution of the wall material. This 
dispersion has to be heated and homogenised and depending on the 
emulsifying properties of the coating agent a emulsifier must be added to 
form a stable emulsion. Then the oil-in-water emulsion is atomised into a 
hot air stream to evaporate the solvent. Due to the short time exposure to 
the heat the core temperature could be kept below 40°C in spite of the high 
temperatures used in the process of spray drying. 
The chemical functionality is determined by the used wall materials. The 
criteria are compatibility with the food product, appropriate particle size, 
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appropriate release, mechanical strength etc. The coating materials can be 
divided into 3 major groups: carbohydrates, gums and proteins. 
Carbohydrates such as maltodextrins, starches or pectin produce stable 
emulsions and exhibit low viscosity, which is necessary for a low particle 
size. 
Gums are used due to their emulsion stabilisation properties and their film 
forming around the core material. Most used among all gums is gum Arabic 
due to its outstanding emulsification properties. 
Out of the huge amount of proteins milk or whey protein and gelatine is 
mostly used for microencapsulation by spray drying. 
Spray drying is the most common and cheapest microencapsulation 
technology. [GHARSALLAOUI et al, 2007] 
Spray drying is a widely used form to microencapsulate omega-3 rich oils 
like fish oil. 
 Microencapsulation by fluidized bed technology 
The aim of this technology is to apply a uniform shell onto solid particles. 
The advantage of this technique is the possibility to use any kind of shell 
material, which enlarges the controlled released possibilities. As coating 
formulations aqueous solutions of hydrocolloids like gums and proteins, 
ethanolic solutions of synthetic polymers and melted fats have been used.  
It is also possible to use the fluidized bed technology as a second step of 
spray drying to enlarge the shelf life of the microcapsules. [GOUIN, 2004] 
 Microencapsulation by spray cooling / chilling 
This technology is routinely used for enzymes, flavours and organic and 
inorganic salts to improve their heat stability, delay release in wet 
environments or to convert liquid hydrophilic ingredients to powders. 
It is more a ‘matrix’ encapsulation than a ‘true’ encapsulation. As a ‘matrix’ 
encapsulation an encapsulation is described where the particles of the 
active ingredient are incorporated in a fat matrix in contrast to a ‘true’ 
encapsulation which has a core/shell type of microcapsules. 
The release cannot be controlled in the way it is possible with other types of 
microencapsulation, because the encapsulated ingredient is released as 
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soon as the capsules come in contact with the food stuff. Further factors 
that affect the release are osmotic forces, slow diffusion of water through 
the shell imperfections, mechanical disruption of the particles and others. 
[GOUIN, 2004] 
 Microencapsulation by extrusion 
Extrusion microencapsulation is used for volatile and unstable flavours 
which leads to a very long shelf life compared to unencapsulated flavour 
compounds like citrus oils. The used glassy carbohydrates build an almost 
impermeable barrier against atmosphere oxygen. 
A mass of modified starch, glycerol and water is mixed and heated up to 
100°C. When it has cooled down the sensitive ingredient, usually a volatile 
flavour is added and then the exiting ropes are cut into pieces. 
This technique offers a high payload – about 40%, which is twice as the 
payload of spray dried flavours – and a long shelf life of about 5 years. The 
disadvantages are the high costs and relatively high particles, which limits 
their application in foods where mouthfeel is a crucial factor. [GOUIN, 2004] 
 Liposome microencapsulation 
Liposome microencapsulation was mostly used for pharmaceutical products 
until recently also the advantages for the food industry became obvious. 
The most appropriate liposomes for food industry are the large unilamellar 
vesicles (LUV). They show high encapsulation efficiency, a good stability 
over time and are easy to produce. The advantage of the liposome 
microencapsulation technology is the targeted delivery of active ingredient 
in specific parts of the foodstuff. Vitamin C encapsulated with this technique 
shows a higher shelf life since it is protected against prooxidants like 
copper. [KIRBY et al., 1991] 
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 Microencapsulation by coacervation 
This technology offers the advantage of a payload up to 99% and a variety 
of application areas like the encapsulation of flavour oils, fish oils, enzymes 
and vitamins. The concept of simple coacervation is based on the phase 
separation of hydrocholloids from an initial solution and a deposition of the 
newly formed coacervate phase around the active ingredient. The shell can 
afterwards be crosslinked with chemicals or enzymes. Coacervation 
systems that exhibit good properties are gelatin/gum arabic system, 
carrageenan, gelatin/carboxymethylcellulose system or starch. 
Complex coacervation involves the use of two oppositely charged 
hydrophilic colloids. In the case of complex coacervation the phase 
separation occurs because of the repulsion of the oppositely charged 
molecules. 
An advanced form is the formation of multi-layered coacervated 
microcapsules which final layer shells can reach a thickness up to 100μm. 
A problem in getting this technique into the food industry is the high cost of 
the process. Some problems can also occur with the use of chemicals as 
crosslinking agents due to the food legislation in some countries which often 
limits the use of such chemicals. [GOUIN, 2004] 
 Microencapsulation by multiple emulsion ( wowCAPS® technology) 
This is a continuous multi-microencapsulation process with interfacial and in 
situ polymerisation of active ingredients.  
The first step is the addition of a water phase containing a polymerisation 
initiator to an oil phase (both of the phases are capable of containing a 
biologically active ingredient) so that an emulsion is built. As a second step 
a solution or dispersion of at least one hydrocholloid in water, e.g. alginates, 
is added to the emulsion to produce a phase inversion. Now a wall of the 
hydrocolloid is built around the new formed drops consisting a water in oil 
emulsion. This wall building is induced by a reaction of alginates with 
calcium, which is enclosed in the water phase of the emulsion. As an 
alginate consists of D-mannuronic acid and L-guluronic acid, which build 
monomeric blocks, the calcium reactivity is a result of calcium-induced 
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dimeric association of the G-blocks. Low amounts of calcium lead to 
temporary associations of the G-blocks, whereas higher amounts obtain 
stronger linkage of the chains. 
 
 
Figure 11: Calcium-induced association of L-guluronic acid [KHYMOS, 2006] 
 
The third step is the addition of a suspension or solution of a protective 
colloid in water, which is deposited on the surface of the water in oil droplets 
to polymerise and cross-link with itself and the hydrocolloid. In a fourth step 
a primary surfactant is added, that allows a reduction of the size of the 
water in oil drops. 
During a fifth step the partially formed microcapsules are deagglomerated 
and reagglomerated which can lead to enclosure of drops inside bigger 
drops. After the formation of the capsules the temperature is increased in 
order to strengthen the wall of the microcapsules. All steps are carried out 
under constant agitation. 
In Figure 12 a built microcapsule is shown. 
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Figure 12: Schematic presentation of GAT wowCAPS® [according to CASAÑA et al, 2006] 
 
The advantages of this technology are the possibility of a targeted release 
at a pH lower than 3 and the protection of the active ingredients against 
oxidation or degradation. [DRUSCH and MANNINO, 2009; CASAÑA et al, 
2006] 
 
In Table 4 compares the most established microencapsulation technologies 
for foods. 
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Table 4: Comparison of microencapsulation technologies [GAT Food Essentials, 2008] 
 
  GATs Micro-
encapsulation 
wowCAPS® 
Matrix-
encapsulation  
Gelatine-
encapsulation 
„coacervation“ 
Characteristics  liquid, w/o/w 
system 
wowCAPS® 
powder, (mostly) 
spray-dried 
powder „powder 
loc“ 
Size of 
capsules  1 – 5 μm 30 - 500 μm > 60 μm 
Release of 
active 
ingredient  targeted release 
with pH < 3.0 
gradual 
incomplete 
release at 
pH < 5.5 
gradual 
incomplete 
release in the 
small intestine by 
stomach acid and 
digestive enzymes 
Protection of 
active 
ingredient  
multiple micro-
encapsulation 
system protected 
in shell of cross-
linked biopolymers 
sponge type 
matrix 
double shell 
matrix, 
encapsulation of 
agglomeration of 
microcapsules 
Product 
stability  
very low free oil 
content (< 1%), 
high protection 
against oxidation 
high surface oil 
levels (> 1%), low 
protection against 
oxidation 
due to shell 
thickness high 
protection against 
oxidation 
Process 
stability  
resistant to 
common 
production 
requirements due 
to small particle 
size 
unstable within 
common 
production 
requirements due 
to big particle size 
suitable for dry 
mixing or addition 
to end product.; 
not suitable for 
high stress 
productions 
processes 
Technology  
natural, GMO-free 
ingredients no 
proteins added 
carrier consisting 
of starch, proteins, 
pectins, sugars or 
other 
fish or pork 
gelatin, 
formaldehyde as 
cross linker 
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3.1 GAT Food Essentials GmbH 
GAT Formulation was founded in 1999 as GAT Formulation GmbH. GAT 
started to provide R&D and analytical service to the agro industry. Since 2004 
research in stabilisation of sensitive ingredients was performed. In 2006 a 
patent for the invented technology was published. The global sales and 
distributions part was expanded and offices in Latin America were founded. 
Since 2008 GAT Food Essentials GmbH is its own entity. 
Various strategic partnerships with leading ingredients providers and long-term 
collaborations with food and beverage companies have enabled the company to 
become a recognised microencapsulation specialist. A growing number of food 
and beverage products containing ingredients using GAT’s microencapsulation 
technology are available on the market all over the world. 
The target market for GAT’s wowCAPS® are long shelf life products with a high 
complexity of the food or beverage application such as low fat UHT milk or 
beverages with a low pH value such as orange juice. 
In 2009 the company won the Frost & Sullivan 2009 Best Practices Award 
“European Functional Food & Beverage Microencapsulation Technology 
Innovation Award”. 
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4.  MATERIALS AND METHODS 
4.1 Chemicals 
Table 5 provides an overview of all chemicals used in this study. 
Table 5: Chemicals used 
Chemical Supplier 
Supplier’s 
catalogue 
reference 
used for: 
AAPH (2,2′-azobis(2-methylpropionamidine) 
dihydrochloride) 
Cayman, Ann 
Arbor 
82235 ORAC assay 
acetone CHROMASOLV for HPLC ≥ 99.9% Sigma,Vienna 270725 
analysis of the fatty 
acid pattern 
acetonitrile VWR, Vienna 20060.320 
analysis of the fatty 
acid pattern 
dichloromethane 
Merck, 
Vienna 
8.22271 
analysis of the fatty 
acid pattern 
dipotassium hydrogen phosphate Sigma,Vienna P 3786 ORAC assay 
cis-4,7,10,13,16,19-docosahexaenoic acid 
methyl ester 98% 
Sigma,Vienna D 2659 
analysis of the fatty 
acid pattern 
docosane, for synthesis, >98%  VWR, Vienna 822046 
analysis of the fatty 
acid pattern 
fluorescein (free acid) Fluka, Vienna 46955 ORAC assay 
n-hexane, HPLC grade VWR, Vienna 104391 
analysis of the fatty 
acid pattern 
(+/-)-6-hydroxy-2,5,7,8-tetramethylchroman-2-
carboxylic acid purum > 98.0% (HPLC) 
(Trolox) 
Fluka, Vienna 56510 ORAC assay 
methyl linolenate – methyl ester of linolenic 
acid, 99% 
Sigma,Vienna 23,526-1 
analysis of the fatty 
acid pattern 
methyl all-cis-5,8,11,14,17-eicosapentaenoate Sigma,Vienna 17266 
analysis of the fatty 
acid pattern 
O-(2,3,4,5,6-Pentafluorobenzyl)hydroxylamine 
hydrochloride (PFBH) 
Fluka, Vienna 76735 
analysis of the fatty 
acid pattern 
potassium dihydrogen phosphate 
Merck, 
Vienna 
1.04873 ORAC assay 
2-propanol 
Merck, 
Vienna 
1.01040 
analysis of the fatty 
acid pattern 
sodium methoxide 0.5M solution in methanol, 
A.C.S. reagent 
Aldrich, 
Vienna 
40,306-7 
analysis of the fatty 
acid pattern 
sodium sulphate VWR, Vienna 1.06649 
analysis of the fatty 
acid pattern 
2,2,4-trimethylpentane, ACS reagent ≥ 99.0% Sigma,Vienna 360597 
UV determination 
of conjugated 
dienes 
37 Components FAME Mix 10 mg/mL in 
CH2Cl2 
Supelco, 
Vienna 
47885-U 
analysis of the fatty 
acid pattern 
44 
 
4.2 Materials 
Table 6 provides an overview of the materials used in this study. 
Table 6: Materials used 
Material Supplier 
Supplier’s 
catalogue 
reference 
used for: 
disposable syringe 
VWR, 
Vienna 
6120109 
analysis of the fatty 
acid pattern 
filter for syringe 
VWR, 
Vienna 
117761Q 
analysis of the fatty 
acid pattern 
glass bottles, amber, 30 mL & 50 mL with screw 
cap 
VWR, 
Vienna 
2151802 
analysis of the fatty 
acid pattern 
96-well assay plate, Optilux, non-sterile 
VWR, 
Vienna 
353293 ORAC assay 
sample cups PP, sterile 
VWR, 
Vienna 
2162690 yogurt production 
vials, amber, 32 x 11.5 mm 
VWR, 
Vienna 
18022494 
analysis of the fatty 
acid pattern 
 
4.3 Apparatus 
1. Agilent 6890N GC equipped with Flame Ionization Detector (FID) and PC 
system with GC ChemStation, Rev. A.09.03, Agilent Technologies Inc. (Inv. 
No. 03/09/34, GC-05) 
 
2. Agilent 6890N GC/MSD equipped with MSD quadrupole 5973 inert mass 
selective detector and Flame Ionization Detector (FID), PC system with 
MSD ChemStation D.02.00.275, Agilent Technologies Inc. (Inv. No. 
05/09/43, GC/MS-06) 
 
3. Agilent HP 1100 HPLC equipped with a degasser (G1379A), quaternary 
pump (G1311A), autosampler (G1315B), PC system with ChemStation for 
LC 3D, Rev. A.10.02, Agilent Technologies Inc. (inv. No. 02/09/17, HPLC-
04) 
 
4. BMG Labtech FLUOstar OPTIMA and PC system with FLUOstar OPTIMA 
software 1.30-0, BMG Labtech GmbH (Inv. No. YY/09/94/02) 
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5. Eppendorf Research 500 – 5000 µL, Eppendorf (Inv. No. 09/05/68/01) 
 
6. Eppendorf Varispenser plus 5 - 25 ml, Dispenser, Eppendorf (Inv. No. 
07/05/57/01 
 
7. Hach DR/4000U Spectrophotometer UV/VIS and HachLink 2000 software 
 
8. Microscope Nikon Alphaphot 2 YS2 (Inv. No. 96/07/01/01) with camera 
Nikon Coolpix 950 (Inv. No. 00/07/03/01) and screen JVC TM 1700PN (Inv. 
No. 00/07/02/01) 
 
9. Sartorius Competence electrical analytical balance CP225D (max. 
40/80/220 g / d= 0.01/0,01/0.1 mg), Sartorius (Inv. No. 03/06/13/01) 
 
10. Sartorius Gem plus electronical precision balance GP5202 (max. 5200g / 
d=0,01g), Sartorius (Inv. No. 04/06/15/01) 
 
11. Ultrasonic bath Sonorex RK 510H / 9,0 L with thermostatic control, Bandelin 
(Inv. No. 04/08/56/01) 
 
4.4 Samples 
4.4.1 Formulation 
The formulation wowCAPS® (in this study also referred to as “the formulation”) 
is a water- in oil- in water (w/o/w) microcapsule suspension containing min. 
7w% EPA/DHA (calculated as free fatty acids from the actual presence in the 
form of glycerides). For this study 100 g samples from a 500 kg production lot 
are taken. They are used for analysis as well as for the application trials. The 
formulation was stored for the time of the experiment (up to 4 weeks) in a cool 
chamber at 3-6 °C or in an oven at 30°C or 70°C respectively. Immediately 
before each trial a fresh bag from the cool chamber is opened. 
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4.4.2 Oil 
The fish oil rich in EPA/DHA (in this study also referred to as “the fish oil”) is 
derived from the species Gadus morhua. The content of EPA/DHA is min. 
26w% (calculated as free fatty acids from the actual presence in the form of 
glycerides). It is provided by a supplier in 9 L bags and is refilled in sterile 
plastic cups for this study. It is used for analysis as well as for the preparation of 
the yoghurt samples. The oil is stored for the time of the experiment (up to 4 
weeks) in the cool house at 3-6 °C or in an oven at 30°C and 70°C respectively. 
The nutritional information of the oil is derived from a standardised oil, but due 
to seasonal variation the content of EPA/DHA is likely to vary. 
Table 7: Nutritional information of fish oil per 100 g 
Energy   900 kcal 
Fat 
 
    
  SFA   23 g 
  MUFA   35 g 
  PUFA   42 g 
 
- of which: ALA 11 g 
  
EPA 13 g 
  
 
DHA 13 g 
    Total ω-3 34 g 
 
4.4.3 Food applications 
4.4.3.1 Yoghurt 
Yoghurt was chosen as food matrix for the thesis for its commercial interest as 
functional food enriched with omega-3.The yogurt is made in-house according 
the recipe in Table 8. 
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Table 8: Yoghurt recipe [in %] 
 
Yoghurt blank 
Yoghurt containing 
wowCAPS
®
 
Yoghurt containing 
fish oil 
Milk 96.98 95.98 96.60 
Milk powder 3.00 3.00 3.00 
Yoghurt cultures 0.02 0.02 0.02 
Formulation wowCAPS
®
 - 1.00 - 
Fish oil - - 0.38 
 
The yoghurt is freshly prepared in the laboratory. Milk is heated in a tempering 
beaker to 85 °C ± 2 °C. Skimmed milk powder is added to achieve a higher dry 
matter. When the milk reaches 85°C ± 2 °C the formulation (1%) and the oil 
(0.38%) respectively is added and the temperature is kept at 85 °C ± 2 °C for 5 
minutes. Then the milk is cooled down to about 43 °C ± 2 °C and the yoghurt 
cultures (Lactobacillus delbrueckii ssp. bulgaricus and Streptococcus salivarius 
ssp. thermophilus) are added. When they are distributed homogenously the 
yoghurt is filled in sterile cups and put into the oven for incubation at 41 °C ± 2 
°C for 4 hours. Afterwards the cups are put in the cool chamber and stored 
before being analyzed. On each time point of analysis a fresh cup is taken out 
of the storage for evaluation. 
4.4.3.2 Cauliflower soup 
Onions are roasted in olive oil and then 1 liter water is added. The cauliflowers 
are cut and cooked in the water. After adding of spices the cauliflowers are 
pureed. Then the formulation wowCAPS® (0.7%) is added. The cauliflower soup 
is analyzed initially and after 1 week storage in the cool house at 3-6 °C. 
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4.4.3.3 Tomato sauce 
Onions are roasted and one package of pure tomato sauce and one can of 
sliced tomatoes are added. Then herbs, salt and pepper are added and the 
sauce is cooked for 15 minutes. Then the formulation wowCAPS® (0.7%) is 
added and the sauce is stirred until the formulation is distributed homogenously. 
Then it is taken off the oven and filled in brown glass bottles for the one week 
storage. The tomato sauce is analyzed initially and after one week storage in 
the cool house at 3-6 °C. 
4.4.3.4 UHT milk 
UHT milk with a fat content of 1.5% enriched with wowCAPS® from an industrial 
trial is delivered to GAT Food Essentials GmbH from a customer. According to 
GAT’s recommendations the milk was enriched with 40 mg EPA/DHA per 250 
mL. The shelf life study is conducted over 3 months at ambient temperature (~ 
20 °C laboratory controlled). 
49 
 
4.5 Analysis of polyunsaturated fatty acids 
4.5.1 Gas Chromatography (GC) 
4.5.1.1 Gas Chromatography with Flame Ionization Detector (FID) 
The GC-FID is used for the quantification of the omega-3 fatty acids in the 
application samples. The validated method for analysis of omega-3 fatty acids 
GAT-0604-FIO01-GC is used. With this method only the fatty acids bond in 
triglycerides are detected. 
 
Chromatographic Parameters 
Column SP2380 Fused Silica Column with stabilized 
cyanosilicone phase 
Injector 250 °C (split 1:100) 
Column oven Gradient programm: 
 start at 150°C hold for 20.0 minutes 
 at 10°C / minute to 240 °C hold for 6 minutes 
Detector FID (Flame Ionisation Detector) at 260 °C 
Flow 1.0 mL / minute 
Carrier gas Helium 
Injection volume 1.0 μL 
Analysis time 35.0 minutes 
 
Sample preparation and analysis 
The sample preparation for this analysis is carried out 4 times for each sample. 
 Fish oil 
 In a bottle approximately 3.75 mg/mL fish oil in n-hexane are weighed 
accurately at 20 ºC. The sample is homogenized in an ultrasonic bath for 
20 minutes. After homogenization the fatty acids are methylated using 
sodium methoxide and again homogenized in an ultrasonic bath for 30 
minutes. The fatty acids methyl esters are analyzed by gas capillary 
chromatography (GC) using a fused silica capillary GC column with a 
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stabilized cyanosilicone phase. The fatty acid methyl esters are 
quantified using docosane as internal standard. 
 Formulation wowCAPS® 
In a bottle approximately 5.0 mg/mL microencapsulated fish oil in n-
hexane are weighed accurately at 20 ºC. The sample is extracted and 
homogenized in an ultrasonic bath for 20 minutes. After extraction from 
the sample the fatty acids are methylated using sodium methoxide and 
again homogenized in an ultrasonic bath for 30 minutes. The emerging 
fatty acid methyl esters are analyzed by gas capillary chromatography 
(GC) using a fused silica capillary GC column with a stabilized 
cyanosilicone phase. The fatty acid methyl esters are quantified using 
docosane as internal standard. 
 Food samples containing wowCAPS® 
In a bottle approximately 12.5 mg/mL food sample containing 
microencapsulated fish oil is weighed at 20 ºC in n-hexane in the 
concentration, which is equal to the amount of formulation of 
microencapsulated fish oil. The sample is extracted in an ultrasonic bath 
for 20 minutes. After extraction from the sample the fatty acids are 
methylated using sodium methoxide and again homogenized in an 
ultrasonic bath for 30 minutes. The fatty acids methyl esters are analyzed 
by gas capillary chromatography (GC) using a fused silica capillary GC 
column with a stabilized cyanosilicone phase. The fatty acid methyl 
esters are quantified using docosane as internal standard. 
Evaluation 
Evaluation is carried out using GC ChemStation, Rev. A.09.03, Agilent 
Technologies Inc. 
4.5.1.2 Gas Chromatography with Mass Sensitive detector (MSD) 
The GC-MSD is used for the qualification of the omega-3 fatty acids in the fish 
oil, the wowCAPS® and the yoghurt samples. 
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Chromatographic Parameters 
Column SP2560 Fused Silica Column 
Injector 250 °C (split 1:100) 
Column oven Gradient program: 
 start at 140 °C hold for 5.0 minutes 
 at 2 °C / minute to 250 °C hold for 10 minutes 
Detector MSD quadrupole (5973 inert mass selective detector) 
Mass parameters EM voltage:  1811 
 Acquisition mode: Scan 
 Scan Group 1 Low Mass: 40.00 amu 
 Scan Group 1 High Mass: 650.00 amu 
 Threshold: 150 counts 
 Sampling rate (2Ùn): 2 
 Scans/sec: 2.42 
 MS Timed Events Table 
 Event type: Detector 
 Detector on: 9.00 min 
 MS temperatures 
 MS source: 230 °C 
 MS quad: 150 °C 
Flow 1.0 mL / minute 
Carrier gas Helium 
Injection volume 2.0 μL 
Analysis time 60.0 minutes 
 
Sample preparation and analysis 
The sample preparation for this analysis is carried out 4 times for each sample. 
 Standards of fatty acids 
Approximately 27 mg of the standards of methyl-linolenate, methyl-EPA 
and methyl-DHA are weighed accurately and dissolved and 
homogenized in 30 mL n-hexane in an ultrasonic bath. The 37 
52 
 
Components FAME Mix (10 mg/mL in CH2Cl2) is injected without further 
preparations. 
 Fish oil 
Approximately 5 g of oil are weighed accurately in a brown glass bottle. 
Then 2 mL of dichloromethane and 1.5 mL of reagent solution (100 mg 
PFBH in 15 mL methanol) are added. The samples are mixed in an 
ultrasonic bath for 15 minutes at fixed temperature of 25 °C. 
 Formulation wowCAPS® 
Approximately 13 g of formulation are weighed accurately in a brown 
glass bottle. Then 1 mL of 0.05 mol HCl is added and the sample is 
mixed in an ultrasonic bath. Then 10 mL of n-hexane are added and the 
sample is put in an ultrasonic bath for 15 minutes at fixed temperature of 
25 °C. Then the sample is centrifugated and 10 mL of the n-hexane 
phase are taken and dried using a rotavapor. The remaining is dissolved 
in 2 mL dichloromethane and 1.5 mL reagent solution (100 mg PFBH in 
15 mL methanol). 
 Food samples containing wowCAPS® 
Approximately 1 g of yoghurt (blank, containing wowCAPS®, containing 
fish oil) is weighed and dissolved in 10 mL n-hexane in an ultrasonic 
bath. Then 3 mL of sodium methoxide is added and mixed in an 
ultrasonic bath for 15 minutes at fixed temperature of 25 °C. 
For this sample preparation no internal standard was used since no 
quantification was done. 
Evaluation 
Evaluation is carried out using MSD ChemStation D.02.00.275, Agilent 
Technologies Inc. 
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4.5.2 High Performance Liquid Chromatography (HPLC) 
4.5.1.2 Reverse Phase High Performance Liquid Chromatography with Diode 
Array Detector (DAD) 
The HPLC analysis is carried out to detect degradation products of fatty acids. 
As most of the degradation products are volatile and unstable under high 
temperature they cannot be detected by gas chromatography. After literature 
review and a pre-test, in which the whole UV-VIS spectrum was measured, the 
wavelengths for detection were chosen accordingly. 
 
Chromatographic Parameters 
Column LiChroCART 250-4 LiChrospher NH2 (5 μm) 
Column oven 20°C for 45 minutes 
Detector DAD (Diode Array Detector) at 216 nm, 234 nm, 275 nm, 
288 nm, 342 nm 
 Spectra 190-500 nm 
Flow 1.0 mL / minute 
Mobile phase n-hexane / acetonitrile (99.75 : 0.25) 
Injection volume 40.0 μL 
Analysis time 45.0 minutes 
 
Sample preparation and analysis 
The sample preparation for this analysis is carried out 4 times for each sample. 
Approximately 1.14 g oil / 3 g formulation is weighed accurately in a brown 
glass bottle. 20 mL n-hexane is added and the sample is put in an ultrasonic 
bath for 20 minutes at fixed temperature of 25 °C. Then 2 mL sodium methoxide 
are added and the sample is put in an ultrasonic bath for another 30 minutes at 
fixed temperature of 25 °C. Then it is centrifugated and the upper phase is 
analyzed by HPLC. 
54 
 
Evaluation 
Evaluation is carried out using ChemStation for LC 3D, Rev. A.10.02, Agilent 
Technologies Inc. The qualification is done according the 3-dimensional scale 
time/wavelength/absorbance. 
 
4.5.3 Peroxide value (method according to Wheeler) 
The peroxide value (PV) measures the amount of peroxides and 
hydroperoxides formed during early stages of lipid oxidation. In more advanced 
stages it is not reliable because hydroperoxides decompose further into other 
products. 
 
The samples are sent to an extern laboratory and are analyzed as follows: 
2.0 – 5.0 g of oil and 5.3 – 13.3 g of formulation respectively are dissolved in 50 
mL isooctane/acetic acid solution (3:2, v/v) and 0.5 mL of saturated potassium 
iodide is added and the mixture is shaken for exactly one minute to form I2: 
 
ROOH + 2 H+ + 2 I- → ROH + I2 + H2O 
 
After the addition of 30 mL water the sample is titrated with 0.01 N sodium 
thiosulfate solution.  
 
I2 + 2 S2O3
2- → 2 I- + S4O6
2- 
 
The PV is expressed in milliequivalents peroxide per kg of sample and is 
calculated as per EN ISO 3960:2007 [ISO, 2007]: 
 
PV = c * v * 16 * 1000 / 2 * m / 8 
 
c = Titrant concentration in mol/L 
v = volume of tritrant in mL 
m = weighed amount of sample in g 
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16 = molecular weight of oxygen 
2 = as 2 moles of titrant correspond to 1 mol of sample 
8 = for meq/kg 
 
4.5.4 UV-VIS Spectrophotometric analysis 
4.5.4.1 Conjugated dienes 
Conjugated dienes (CD) are intermediate products in the early stages of 
oxidation. They react with oxygen to from conjugated hydroperoxides. The most 
representative absorption maximum is at 234 nm and can be measured 
spectrophotometrically. 
 
56 mg of formulation with 2 mL of acidified water (pH 2) for breaking the 
capsules and 20 mg of oil respectively are weighed into a 20 mL volumetric 
flask which is filled with isooctane (2,2,4-trimethylpentane) up to the 20 mL 
mark. The flasks are put into an ultrasonic bath to obtain a homogenous 
distribution. The absorbance was measured using a Hach DR/4000U 
spectrophotometer at 234 nm against a blank of isooctane. 
To ensure that there is no interference a test with oil and acidified water is 
carried out. 
 
The CD values are calculated as described in the AOCS official method Ti 1a-
64 [AOCS, 1998]: 
 
CD, % = 0.84 [(As/b*c)-K0] 
 
As = absorbency at 234 nm 
b = cuvette length in cm 
c = sample concentration in isooctane (g/L) 
K0 = absorptivity by acid or ester groups; 0.07 for esters, 0.03 for acids 
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4.5.4.2 Conjugated trienes 
Conjugated trienes (CT) are intermediate products in the early stages of 
oxidation. They react with oxygen to from conjugated hydroperoxides. The most 
representative absorption maximum is at 268 nm and can be measured 
spectrophotometrically. 
 
56 mg of formulation with 2mL of acidified water (pH 2) for breaking the 
capsules and 20 mg of oil respectively are weighed into a 20 mL volumetric 
flask which is filled with isooctane (2,2,4-trimethylpentane) up to the 20 mL 
mark. The flasks are put into an ultrasonic bath to obtain a homogenous 
distribution. The absorbance was measured using a Hach DR/4000U 
spectrophotometer at 268 nm against a blank of isooctane. 
To ensure that there is no interference a test with oil and acidified water is 
carried out. 
 
The CT values are calculated as described in the AOCS official method Ti 1a-
64 [AOCS, 1998]: 
 
CT, % = 0.84 [(As/b*c)-K0] 
 
As = absorbency at 268 nm 
b = cuvette length in cm 
c = sample concentration in isooctane (g/L) 
K0 = absorptivity by acid or ester groups; 0.07 for esters, 0.03 for acids 
 
4.5.5 Fluorometric analysis – ORAC assay 
The ORAC (oxygen radical antioxidative capacity) assay is used to determine 
the antioxidative capacity of the tested samples. While this test is well 
developed for water soluble compounds, ORAC analysis for water-insoluble 
compounds is still lacking of adequate testing methodology. It measures the 
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decrease in the fluorescence of fluorescein as a result of its degradation when it 
is oxidatively damaged by a source of peroxyl radicals. 
 
The automated ORAC assay is carried out on a FLUOstar OPTIMA with 
fluorescein as the “fluorescent source” and AAPH radical as the catalysator. 
The reaction is performed at 37 °C as the reaction is started by thermal 
decomposition of AAPH (2,2′-azobis(2-methylpropionamidine) dihydrochloride). 
As fluorescein is sensitive to pH the solvent is a 75mMol phosphate buffer with 
pH 7.4. As standard trolox ((+/-)-6-hydroxy-2,5,7,8-tetramethylchroman-2-
carboxylic acid) is used in 5 different dilutions. 
As the ORAC assay is very sensitive to oxidation the solvent and all reagents, 
standards and samples have to be made daily fresh before analysis. 
The samples (75 mg of formulation, 28.5 mg of oil, 1800 mg of yoghurt, 
respectively) and standards (10 mg trolox) are diluted in 30 mL phosphate 
buffer solution and further dilutions are made. To enable the dilution of the oil an 
emulsion is prepared. The same emulsion without the oil is tested as blank. 
Then to each of the samples 150 µL of fluorescein is added and they are put in 
the FLUOstar OPTIMA to measure their antioxidative capacity. After 3 runs 25 
µL of the reagent AAPH is added to catalyze the reaction of forming oxidative 
radicals. Then the decrease of the ability to fluoresce is measured. 
The ORAC values are calculated by following formula and expressed as μMol 
trolox equivalents (TE). 
 
 
ORAC [μmol TE] = 
(CTrolox * (AUCSample – AUCBlank) * k) 
(AUCTrolox – AUCBlank) 
 
 
AUC = area under the curve 
CTrolox = is the concentration of Trolox 
k = sample dilution factor 
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Figure 13 shows an image of the evaluation of the ORAC essay as example. 
 
Figure 13: Image of ORAC essay evaluation 
 
4.6 Sensory evaluation 
For the sensory evaluation a panel of 8 persons of GAT was established 
according general guidelines for this purpose. The samples are 
indistinguishable to the panel and are taken from the cool house 3 hours before 
tasting to warm them up. The panel has to evaluate the samples on color, 
cloudiness, surface appearance, consistency, smell, taste, aftertaste and mouth 
feel. All these terms are used to determine the general impact, whereas smell, 
taste and aftertaste are used to determine off-flavor. The range of acceptability 
is chosen due to a long experience in this kind of tastings. The scale is set to 0 
for least acceptability and 8 for highest acceptability. The scale of the overall 
acceptability is set to like, neutral and dislike. 
As samples yoghurt, cauliflower soup, and tomato sauce are taken. One tasting 
per day is scheduled. The evaluation of the tastings is carried out with MS 
Excel. 
 
AUC 
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4.7 Microscopic observation 
Microscopic observation of the microencapsulated product and the food 
samples is carried out to show if the capsules undergo any changes throughout 
the production processes of the food samples and to assess microscopical 
changes in the food structure. 
 
Sample preparation and analysis 
 Formulation wowCAPS® 
20 g of deionized water are weighed in an amber glass bottle. 1 g of 
wowCAPS® is added and emulsified. A small drop of it is placed on the 
microscope slide and covered with a cover glass. 
 Yoghurt containing wowCAPS® 
5 g of deionized water are weighed in an amber glass bottle. 5 g of 
yoghurt containing wowCAPS® is added and shaken by hand. A small 
drop of it is placed on the microscope slide and covered with a cover 
glass. 
 Yoghurt containing fish oil 
5 g of deionized water are weighed in an amber glass bottle. 5 g of 
yoghurt containing fish oil is added and shaken by hand. A small drop of 
it is placed on the microscope slide and covered with a cover glass. 
 Cauliflower soup, tomato sauce, UHT milk containing wowCAPS® 
5 g of deionized water are weighed in an amber glass bottle. 5 g of the 
sample containing wowCAPS® is added and homogenized by hand. A 
small drop of it is placed on the microscope slide and covered with a 
cover glass. 
 
4.8 Statistical analysis 
Statistical analysis has been performed with the software package OriginPro 8.0 
SR0, v. 8.0724 (B724) running in a PC equipped with Windows 7 operative 
system.  
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Grubb’s test for detecting outliers is used to find outliers in the data of the 
omega-3 analysis of the yoghurt containing wowCAPS®. 
For the analysis of the omega-3 values in yoghurt One-Way ANOVA is used. To 
determine the significance of the values of the conjugated dienes and trienes 
One-Way ANOVA as well as the Fisher-Test is used. 
For organoleptic evaluation One-Way ANOVA is used. 
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5.  RESULTS & DISCUSSION 
5.1 Analysis of polyunsaturated fatty acids in formulation, oil, 
and ω-3 fortified yogurt, cauliflower soup, tomato sauce and 
UHT milk 
Evaluation of the analysis is limited to the evaluation of EPA and DHA as these 
are the primary components of marine fish oils. As the content of EPA and DHA 
is very high in these oils it is easier to analyze them in complex matrices. We 
assume that the organoleptic and chemical properties of the other ω-3 fatty 
acids follow the same pattern. 
 
CHANGES OF ω-3 FATTY ACIDS OVER TIME 
5.1.1 GC - FID 
5.1.1.1 Formulation wowCAPS® 
Figure 14 shows the GC-FID chromatogram of the quantitative fatty acid 
analysis of the formulation wowCAPS®. 
 
Figure 14: GC-FID chromatogram of formulation wowCAPS
®
 
 
ALA 
EPA 
DHA 
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Figure 15 shows an outtake of the GC-FID chromatogram of the quantitative 
fatty acid analysis of the formulation wowCAPS®. 
 
Figure 15: GC-FID chromatogram of formulation wowCAPS
®
 (outtake) 
 
Table 9 shows the results of the quantitative fatty acid analysis of wowCAPS® 
with GC-FID. 
Table 9: Fatty acid analysis of formulation wowCAPS
®
 
Omega-3 fatty acids mg/100g 
all cis-9,12,15-Octadecatrienoic acid ω3 
(α-Linolenic acid) 
290 
all cis-6,9,12,15-Octadecatetraenoic acid ω3 430 
all cis-8,11,14,17-Eicosatetraenoic acid ω3 230 
all cis-5,8,11,14,17-Eicosapentaenoic acid ω3 (EPA) 4630 
all cis-7,10,13,16,19-Docosapentaenoic acid ω3 (DPA) 760 
all cis-4,7,10,13,16,19-Docosahexaenoic acid ω3 (DHA) 3540 
TOTAL omega-3 9880 
EPA/DHA 8170 
ALA 
EPA 
DHA 
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5.1.1.2 Fish oil 
Figure 16 shows the GC-FID chromatogram of the quantitative fatty acid 
analysis of the fish oil. 
 
Figure 16: GC-FID chromatogram of fish oil  
 
Figure 17 shows an outtake of the GC-FID chromatogram of the quantitative 
fatty acid analysis of the fish oil. 
 
Figure 17: GC-FID chromatogram of fish oil (outtake) 
 
ALA 
EPA 
DHA 
ALA 
EPA 
DHA 
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Table 10 shows the results of the quantitative fatty acid analysis of fish oil with 
GC-FID. 
Table 10: Fatty acid analysis of fish oil 
Omega-3 fatty acids mg/100g 
all cis-9,12,15-Octadecatrienoic acid ω3 
(α-Linolenic acid) 
750 
all cis-6,9,12,15-Octadecatetraenoic acid ω3 1390 
all cis-8,11,14,17-Eicosatetraenoic acid ω3 750 
all cis-5,8,11,14,17-Eicosapentaenoic acid ω3 (EPA) 14230 
all cis-7,10,13,16,19-Docosapentaenoic acid ω3 (DPA) 2400 
all cis-4,7,10,13,16,19-Docosahexaenoic acid ω3 (DHA) 10970 
TOTAL omega-3 30490 
EPA/DHA 25200 
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5.1.1.3 Yoghurt 
Figure 18 shows the GC-FID chromatogram of the quantitative fatty acid 
analysis of the blank yoghurt at the time point of initial analysis. 
 
Figure 18: GC-FID chromatogram of yoghurt blank, initial 
 
Figure 19 and Figure 20 show the GC-FID chromatograms of the quantitative 
fatty acid analysis of the yoghurt containing wowCAPS® at the time point of 
initial analysis (blue) and after 21 days storage at 3-6 °C (red). 
 
Figure 19: GC-FID chromatogram of yoghurt containing wowCAPS
®
 
 
ALA 
EPA DHA 
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Figure 20: GC-FID chromatogram of yoghurt containing wowCAPS
®
 
 
The changes in the base line of the different analyses are the results of 
unavoidable conversions of the apparatus. 
 
In Table 11 the results of the quantitative fatty acid pattern analysis of the 
yoghurt enriched with wowCAPS® at each time point of the storage stability 
testing is shown. A deviation in both increase and decrease occurs throughout 
the storage time. This could be referred to an inhomogeneous distribution of the 
formulation in the milk prior to filling and fermentation. Further research on this 
topic would be necessary as the possibilities in the laboratory were limited with 
regard to the production process of yoghurt. 
EPA 
ALA 
DHA 
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Table 11: Fatty acid analysis of homemade yoghurt enriched with wowCAPS
® 
(n.d. – not 
detectable) 
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Figure 21 and Figure 22 show the GC-FID chromatogram of the quantitative 
fatty acid analysis of the yoghurt containing fish oil at the time point of initial 
analysis (blue) and after 21 days storage at 3-6 °C (red). 
 
Figure 21: GC-FID chromatogram of yoghurt containing fish oil 
 
 
Figure 22: GC-FID chromatogram of yoghurt containing fish oil 
 
In Table 12 the outcome of the quantitative fatty acid pattern analysis of the 
yoghurt enriched with fish oil at each time point of the storage stability testing is 
shown. 
ALA 
EPA DHA 
EPA 
ALA 
DHA 
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Table 12: Fatty acid analysis of homemade yoghurt enriched with fish oil (n.d. – not 
detectable) 
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Statistical analysis of the stability of the omega-3 fatty acids incorporated into 
yogurt samples 
The results shown in Table 11 and Table 12 have been subjected to a series of 
One-Way ANOVA statistical analysis. 
Some of the omega-3 fatty acids, namely all cis-6,9,12,15-Octadecatetraenoic 
acid and all cis-8,11,14,17-Eicosatetraenoic acid have been excluded from the 
calculations, as they show interferences due to the presence of a high baseline 
caused by the food matrix (see Figure 20 and Figure 22).  Similarly any outlier 
has been deleted from the analysis (day 4 and 5 for DPA; for the sake of having 
a balanced design such values have been disregarded in both set of data, the 
one with pure fish oil and the one with wowCAPS®). The verification of the 
condition of outlier has been performed with the online test 
http://www.graphpad.com/quickcalcs/Grubbs1.cfm at alpha = 0,01. 
For the purpose of this work the analytical method GAT-0604-FIO01-GC used 
in this experimental part has shown to be precise and specific enough for a 
correct determination of the most important omega-3 from an industrial point of 
view, namely EPA and DHA [GAT FORMULATION, 2004]. The content in EPA 
and DHA in the final products is normally what is reflected in the label of the 
functional food as the claimed content of omega-3. 
The One-Way ANOVA shows that there are significant differences (p < 0.05) in 
the EPA, DPA and DHA content depending on the form of application: in the 
yoghurt, the wowCAPS® formulation provides more stability over time for EPA, 
DPA and DHA than the simple addition of fish oil. 
Additionally it has been observed (in the most aged yoghurt samples) that the 
fish oil, when added directly and not via wowCAPS®, separates in certain 
regions of the yoghurt. Although the samples of yoghurt were homogenized 
carefully before taking the aliquots for the analyses the wowCAPS® formulation 
provides more homogeneity in the distribution of the omega-3 in yoghurt 
samples than the simple addition of fish oil. 
It is noted, that a relatively high variability of the results within the same type of 
dosage form has been observed, although this fact does not prevent to find 
statistically significant differences. 
71 
 
As the possibilities in the laboratory at GAT Food Essentials GmbH are limited 
when it comes to the production of food samples containing either wowCAPS® 
or fish oil further trials to confirm the findings of this study are necessary. 
5.1.1.4 Cauliflower soup 
Figure 23 and Figure 24 show the GC-FID chromatogram of the quantitative 
fatty acid analysis of cauliflower soup enriched with wowCAPS® at the time 
point of initial analysis (blue) and after 1 week storage at 3-6 °C (red). 
 
Figure 23: GC-FID chromatogram of cauliflower soup containing wowCAPS
®
 
 
 
Figure 24: GC-FID chromatogram of cauliflower soup containing wowCAPS
®
 after 1 week 
of storage 
EPA 
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The olive oil used for the preparation of the cauliflower soup does not interfere 
with the analysis of the ω-3 fatty acids. 
 
Table 13 shows the results of the fatty acid analysis of cauliflower soup 
enriched with wowCAPS® initially and after one week of storage at 3-6 °C. 
 
Table 13: Fatty acid analysis of homemade cauliflower soup enriched with wowCAPS
®
 
Omega-3 fatty acids 
theory initial 1 week 
mg/100 g mg/100 g mg/100 g 
all cis-9,12,15-Octadecatrienoic 
acid ω3 (α-Linolenic acid) 
2.03 interferences interferences 
all cis-6,9,12,15-
Octadecatetraenoic acid ω3 
3.01 not detectable not detectable 
all cis-8,11,14,17-Eicosatetraenoic 
acid ω3 
1.61 not detectable not detectable 
all cis-5,8,11,14,17-
Eicosapentaenoic acid ω3 (EPA) 
32.41 33.42 ± 0.92 32.61 ± 0.86 
all cis-7,10,13,16,19-
Docosapentaenoic acid ω3 (DPA) 
5.32 not detectable not detectable 
all cis-4,7,10,13,16,19-
Docosahexaenoic acid ω3 (DHA) 
24.78 30.55 ± 2.05 24.46 ± 1.25 
TOTAL omega-3 69.16 not calculable not calculable 
Deviation to the initial in % - - not calculable 
EPA/DHA 57.19 63.97 57.07 
Deviation to the initial in % - - -10.79 
 
As some compounds interfered with the peak of ALA these values cannot be 
included. 
No appraisable difference is detected between the initial values and the values 
after 1 week storage. 
5.1.1.5 Tomato sauce 
Figure 25 and Figure 26 show the GC-FID chromatogram of the quantitative 
fatty acid analysis of tomato sauce enriched with wowCAPS® at the time point 
of initial analysis (blue) and after 1 week storage at 3-6 °C (red). 
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Figure 25: GC-FID chromatogram of tomato sauce containing wowCAPS
®
 
 
 
Figure 26: GC-FID chromatogram of tomato sauce containing wowCAPS
®
 after 1 week of 
storage 
 
Table 14 shows the results of the fatty acid analysis of tomato sauce enriched 
with wowCAPS® initially and after one week of storage at 3-6 °C. 
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Table 14: Fatty acid analysis of homemade tomato sauce enriched with wowCAPS
®
 
Omega-3 fatty acids 
theory initial 1 week 
mg/100 g mg/100 g mg/100 g 
all cis-9,12,15-Octadecatrienoic 
acid ω3 (α-Linolenic acid) 
2.03 not detectable not detectable 
all cis-6,9,12,15-
Octadecatetraenoic acid ω3 
3.01 not detectable not detectable 
all cis-8,11,14,17-Eicosatetraenoic 
acid ω3 
1.61 not detectable not detectable 
all cis-5,8,11,14,17-
Eicosapentaenoic acid ω3 (EPA) 
32.41 31.31 ± 3.62 33.04 ± 1.09 
all cis-7,10,13,16,19-
Docosapentaenoic acid ω3 (DPA) 
5.32 0.89 ± 2.53 not detectable 
all cis-4,7,10,13,16,19-
Docosahexaenoic acid ω3 (DHA) 
24.78 23.63 ± 1.79 24.49 ± 1.79 
TOTAL omega-3 69.16 55.84 57.53 
Deviation to the initial in % - - 3.04 
EPA/DHA 57.19 54.94 57.53 
Deviation to the initial in % - - 4.72 
 
No significant difference is detected between the initial values and the values 
after 1 week storage. 
5.1.1.7 UHT milk 
Figure 27 and Figure 28 show the GC-FID chromatogram of the quantitative 
fatty acid analysis of UHT milk enriched with wowCAPS® at the time point of 
initial analysis (blue) and after 3 months storage at room temperature (red). 
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Figure 27: GC-FID chromatogram of UHT milk containing wowCAPS
®
 
 
 
Figure 28: GC-FID chromatogram of UHT milk containing wowCAPS
®
 after 3 months of 
storage 
 
In Table 15 the results of the analysis of UHT milk enriched with wowCAPS® 
from an industrial trial are shown. Analysis was done initially, after 1 month and 
after 3 months of storage. The theoretical values are based on the Certificate of 
Analysis of the used formulation and the actual addition of this formulation. The 
high values of ALA might be influenced by the milk or other ingredients used. 
EPA DHA 
EPA 
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Table 15: Fatty acid analysis of UHT milk enriched with wowCAPS
®
 produced by customer 
Omega-3 fatty acids 
theory initial 1 month 3 months 
mg/250 mL mg/250 mL mg/250 mL mg/250 mL 
all cis-9,12,15-Octadecatrienoic 
acid ω3 (α-Linolenic acid) 
1.42 13.52 ±0.25 14.73 ±0.81 13.98 ±0.75 
all cis-6,9,12,15-
Octadecatetraenoic acid ω3 
2.11 
not 
detectable 
not 
detectable 
not 
detectable 
all cis-8,11,14,17-Eicosatetraenoic 
acid ω3 
1.12 
not 
detectable 
not 
detectable 
not 
detectable 
all cis-5,8,11,14,17-
Eicosapentaenoic acid ω3 (EPA) 
22.67 29.16 ±0.96 28.41 ±0.48 25.62 ±0.66 
all cis-7,10,13,16,19-
Docosapentaenoic acid ω3 (DPA) 
3.72 5.48 ±0.14 6.56 ±0.40 5.68 ±0.36 
all cis-4,7,10,13,16,19-
Docosahexaenoic acid ω3 (DHA) 
17.33 11.26 ±0.38 11.19 ±0.40 9.98 ±0.19 
TOTAL omega-3 48.37 59.42 60.89 55.26 
Deviation to the initial in % - - -4.16 -7.00 
EPA/DHA 40.00 40.42 39.60 35.60 
Deviation to the initial in %  - -2.03 -11.92 
 
No significant difference is detected between the initial values and the values 
after 3 months storage. 
 
CHANGES OF ω-3 FATTY ACIDS WITH TEMPERATURE 
5.1.2 GC – MS 
These analyses have been performed in order to confirm the molecular 
structure of the PUFAs and to assess if storage at elevated temperatures shows 
degradation products. 
5.1.2.1 Standards of fatty acids 
Figure 29 shows the GC-MS chromatogram of the analytical standard of methyl 
linolenate. 
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Figure 29: GC-MS chromatogram: methyl linolenate – methyl ester of linolenic acid, 99% 
 
In Figure 30 the mass spectrum of methyl linolenate of the analytical standard 
and the database reference is shown. 
 
Figure 30: GC-MS spectrum: methyl linolenate – methyl ester of linolenic acid, 99% 
 
Figure 31 shows the GC-MS chromatogram of methyl all-cis-5,8,11,14,17-
Eicosapentaenoate. 
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Figure 31: GC-MS chromatogram: methyl all-cis-5,8,11,14,17-Eicosapentaenoate 
 
Figure 32 shows the mass spectrum of the injected analytical standard methyl 
all-cis-5,8,11,14,17-Eicosapentaenoate and the database reference. 
 
Figure 32: GC-MS spectrum: methyl all-cis-5,8,11,14,17-Eicosapentaenoate 
 
Figure 33 shows the GC-MS chromatogram of cis-4,7,10,13,16,19-
Docosahexaenoic acid methyl ester. 
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Figure 33: GC-MS chromatogram: cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester 
98% 
 
Figure 34 shows the mass spectrum of the injected analytical standard cis-
4,7,10,13,16,19-Docosahexaenoic acid methyl ester and the database 
reference. 
 
Figure 34: GC-MS spectrum: cis-4,7,10,13,16,19-Docosahexaenoic acid methyl ester 98% 
 
Figure 35 shows the GC-MS chromatogram of the 37 components FAME Mix 
standard. 
DHA 
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Figure 35: GC-MS chromatogram: 37 components FAME Mix 10 mg/mL in CH2Cl2 
 
Figure 36 shows parts of the GC-MS chromatogram of the 37 components 
FAME Mix standard. 
 
Figure 36: GC-MS chromatogram: 37 components FAME Mix 10 mg/mL in CH2Cl2 
(outtake) 
 
The comparison of the previously shown FA standards confirm the correct 
identification in the formulation wowCAPS® based on retention time and mass 
spectrum. 
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5.1.2.2 Formulation wowCAPS® 
In Figure 37 the GC-MS chromatogram of the formulation wowCAPS® stored at 
3-6 °C for 4 weeks is shown. 
 
Figure 37: GC-MS chromatogram: wowCAPS
®
 stored at 3-6 °C for 4 weeks 
 
Figure 38 shows the GC-MS chromatogram of the formulation wowCAPS® 
stored at 30 °C for 4 weeks. 
 
Figure 38: GC-MS chromatogram: wowCAPS
®
 stored at 30 °C for 4 weeks 
 
Figure 39 shows the GC-MS chromatogram of the formulation wowCAPS® 
stored at 70 °C for 4 weeks. 
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Figure 39: GC-MS chromatogram: wowCAPS
®
 stored at 70 °C for 4 weeks 
 
Figure 40 shows an overlay of the GC-MS chromatograms of the wowCAPS® 
stored at 3-6 °C, 30 °C and 70 °C for 4 weeks. 
 
Figure 40: GC-MS chromatogram: comparison of wowCAPS
®
 stored at 3-6 °C (red), 30 °C 
(green) and 70 °C (blue) for 4 weeks 
 
The used method is valid for all samples because independently of the storage 
temperature the same peaks are identified. 
 
It was decided to show the GC-MS spectra of the different fatty acids just for the 
standards and the fish oil as it is more clearly represented there. 
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5.1.2.3 Fish oil 
Figure 41 shows the GC-MS chromatogram of the fish oil stored at 3-6 °C for 4 
weeks. 
 
Figure 41: GC-MS chromatogram: fish oil stored at 3-6 °C for 4 weeks 
 
Figure 42 shows the mass spectrum of EPA in the fish oil stored at 3-6 °C for 4 
weeks. 
 
Figure 42: GC-MS spectrum EPA: fish oil stored at 3-6 °C for 4 weeks 
 
Figure 43 shows the mass spectrum of DHA in the fish oil stored at 3-6 °C for 4 
weeks. 
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Figure 43: GC-MS spectrum DHA: fish oil stored at 3-6 °C for 4 weeks 
 
Figure 44 shows the GC-MS chromatogram of the fish oil stored at 30 °C for 4 
weeks. 
 
Figure 44: GC-MS chromatogram: fish oil stored at 30 °C for 4 weeks 
 
Figure 45 shows the GC-MS chromatogram of the fish oil stored at 70 °C for 4 
weeks. 
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Figure 45: GC-MS chromatogram: fish oil stored at 70 °C for 4 weeks 
 
Figure 46 shows the mass spectrum of EPA in the fish oil stored at 70 °C for 4 
weeks. 
 
Figure 46: GC-MS spectrum EPA: fish oil stored at 70 °C 
 
Figure 47 shows the mass spectrum of DHA in the fish oil stored at 70 °C for 4 
weeks. 
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Figure 47: GC-MS spectrum DHA: fish oil stored at 70 °C 
 
Figure 48 shows an overlay of the GC-MS chromatograms of the fish oil stored 
at 3-6 °C, 30 °C and 70 °C for 4 weeks. 
 
Figure 48: GC-MS chromatogram: comparison of fish oil stored at 3-6 °C (red), 30 °C 
(green) and 70 °C (blue) for 4 weeks 
 
The used method is valid for all samples because independently of the storage 
temperature the same peaks are identified. 
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5.1.2.4 Yoghurt 
Figure 49 shows the GC-MS chromatogram of a blank yoghurt sample. 
 
Figure 49: GC-MS chromatogram: yoghurt blank 3-6 °C 
 
Figure 50 shows the GC-MS chromatogram of a yoghurt sample containing 
wowCAPS®. Only the peaks of ALA and EPA are visible since the random noise 
is too high to detect the peak of DHA. 
 
Figure 50: GC-MS chromatogram: yoghurt containing wowCAPS
®
 3-6 °C 
 
Figure 51 shows the GC-MS chromatogram of a yoghurt sample fish oil. Only 
the peak of ALA is visible because since the random noise is too high to detect 
the peaks of EPA and DHA. 
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Figure 51: GC-MS chromatogram: yoghurt containing fish oil 3-6 °C 
 
None of the used GC-MS analyses are able to reveal a significant decrease of 
any of the omega-3 FA due to increased storage temperature stress. 
Furthermore no decomposition products (e.g. aldehydes, ketones, etc.) could 
be detected in any sample. 
 
5.1.3 HPLC – DAD 
With a single wavelength display, or even with overlaid wavelengths display, it 
is very difficult to see differences among the tested samples. Therefore, various 
display options have been evaluated. The isoplot function shown below is not 
routinely used in the presentation of results from HPLC-DAD analysis, However, 
we have noted that is the best option to make differences visible. The reason is 
that the variations in absorption are difficult to be shown with individually 
selected wavelengths, since the baseline(s) are relatively high. 
 
The parameters of the isoplot function are: 
Fit: auto (higer intensity color: red; lower intensity color: blue) 
Scale: log 
Zero: 0.0 mAU 
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Note: The amount of chromatograms shown in this chapter has been limited for 
the sake of clarity. The tests have been performed at time zero, and for each 
sample (except UV irradiated) after 4 weeks at either 30 °C or 70 °C. 
5.1.3.1 Formulation wowCAPS® at 30 °C and 70 °C 
Figure 52 shows the chromatogram of the analysis of the formulation 
wowCAPS® stored at 30 °C for 4 weeks. 
 
Figure 52: HPLC-DAD chromatogram (log): wowCAPS
®
, 4 weeks at 30 °C 
 
Figure 53 shows the chromatogram of the analysis of the formulation 
wowCAPS® stored at 70 °C for 4 weeks. 
 
Figure 53: HPLC-DAD chromatogram (log): wowCAPS
®
, 4 weeks at 70 °C 
 
The comparison of the plots shows a decrease in intensity of fatty acid signals 
from ca. min 24 to min 43 (under the white curly brace). This effect is 
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comparable in the experiments below with the fish oil whether treated with heat 
or UV irradiation to the extent that the higher the oxidation, the darker and 
broader is the blue area. 
We can observe a slight increase in the area under the opened circle (pointed 
with the arrows). In the case of the wowCAPS, this increase between the 30 ºC 
and the 70 °C storage is mild but still appreciable. 
The signals inside the black rectangle are specific for coformulants present in 
the wowCAPS® formulation and are to be disregarded. 
5.1.3.2 Fish oil at different temperatures at 3-6 °C, 30 °C and 70 °C  
Figure 54 show the chromatogram of the analysis of the fish oil stored at 3-6 °C 
for 4 weeks. 
 
Figure 54: HPLC-DAD chromatogram (log): fish oil, 4 weeks at 3-6 °C 
 
Figure 55 shows the chromatogram of the analysis of the fish oil stored at 30 °C 
for 4 weeks. 
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Figure 55: HPLC-DAD chromatogram (log): fish oil, 4 weeks at 30 °C 
 
Figure 56 shows the chromatogram of the analysis of the fish oil stored at 70 °C 
for 4 weeks. 
 
Figure 56: HPLC-DAD chromatogram (log): fish oil, 4 weeks at 70 °C 
5.1.3.3 Fish oil irradiated with UV at 254 nm 
Figure 57 shows the chromatogram of the analysis of the fish oil treated with UV 
at 254 nm for 5 hours.  
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Figure 57: HPLC-DAD chromatogram (log): fish oil, UV 254 nm 
 
Remarkably, the spot marked with a circle shows a deeper (towards the red 
end) color in the area that for the 3 experiment sets seems to indicate a marker 
for oxidation. 
It seems that instead of showing a higher absorption at 234 nm (conjugated 
dienes) or at 268 nm (conjugated trienes), in these experiments, the increase of 
oxidation is better observed at the range 240 – 250 nm (with a maximum at 245 
nm). 
The reason behind this preferential wavelength when evaluating oxidized 
products remains unknown in this study. It is hypothesized that it must 
correspond to a (some) fatty acid(s) or fatty acid derivative(s) whose formation 
is independent from a plain free radical induced oxidation (UV irradiation) or a 
temperature induced oxidation. But it is to say that this hypothesis is very 
unlikely and needs to be proved. 
 
5.1.4 Peroxide value 
The determination of the peroxide value was carried out by the The Hungarian 
Dairy Research Institute (MTKI), Mosonmagyaróvár (Hungary) according the 
method ISO 3960:2007. The testing of the peroxide value was carried out in 
duplicate. 
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The self-made yoghurts were stored for 9 weeks at 3-6 °C and 30 °C and then 
sent for analysis to the external MTKI laboratory. The results are shown in 
Table 16. 
Table 16: Peroxide values of self-made yoghurts after 1 month storage 
Sample storage 
peroxide value [meq/kg] 
(average of 2 measurements) 
Yoghurt Blank 3-6 °C not detectable 
Yoghurt Blank 30 °C not detectable 
Yoghurt containing wowCAPS
®
 3-6 °C not detectable 
Yoghurt containing wowCAPS
®
 30 °C not detectable 
Yoghurt containing fish oil 3-6 °C not detectable 
Yoghurt containing fish oil 30 °C 1.08 
 
The results in Table 16 show that only in the sample with the plain oil, stored at 
30 °C to simulate an accelerated storage, a peroxide value of 1.08 meq/kg 
could be detected. 
The fish oil and the wowCAPS® were stored at 3-6 °C, 30 °C and 70 °C for one 
week to simulate an accelerated storage and then sent for analysis to the 
external MTKI laboratory. The results are shown in 17. 
Table 17: Peroxide values of formulations and oils 
Sample storage 
peroxide value [meq/kg] 
(average of 2 measurements) 
wowCAPS
®
 3-6 °C not detectable 
wowCAPS
®
 30 °C not detectable 
wowCAPS
®
 70 °C 0.65 
Fish oil 3-6 °C not detectable 
Fish oil 30 °C not detectable 
Fish oil 70 °C 3.99 
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The results in Table 17 show that in the fish oil sample stored at 70 °C a higher 
peroxide value is detected than in the sample of wowCAPS® stored at 70 °C. 
From this can be said that the formulation wowCAPS® is a protection for the fish 
oil against oxidation. The values were expected to be higher. 
 
5.1.5 UV-VIS Spectrophotometric analysis 
5.1.5.1 Conjugated dienes 
Storage of the yoghurt at 30 °C caused an increase of conjugated dienes (CD) 
compared with the yoghurt stored at 3-6 °C. The yoghurts were stored at these 
temperatures for 9 weeks. 
This occurred for the yoghurt enriched with the formulation wowCAPS® as well 
as for the yoghurt enriched with fish oil. The conjugated dienes values are 
higher in both samples of the yoghurt enriched with oil than in the yoghurt 
containing formulation. 
Table 18: Conjugated dienes [%] of yoghurts containing formulation wowCAPS
® 
and fish oil 
Sample 
Average (n=4) 
[%] 
Standard Deviation 
(n=4) 
Yogurt containing wowCAPS
®
 3-6°C 0.202 0.140 
Yogurt containing wowCAPS
®
 30°C 0.890 0.132 
Yogurt containing fish oil 3-6°C 0.674 0.176 
Yogurt containing fish oil 30°C 1.617 0.135 
 
95 
 
 
Figure 58: Conjugated diene values of yoghurts containing formulation wowCAPS
®
 and 
fish oil  
 
As seen in Figure 59 below the application of the oil into the yoghurt showed an 
high impact on conjugated dienes. Conjugated dienes in the yoghurt containing 
formulation wowCAPS® are significantly lower that in the yoghurt containing fish 
oil (p < 0.05). 
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Figure 59: Means and standard errors of the conjugated dienes of the yogurt containing 
formulation wowCAPS
®
 and the fish oil according the application form 
 
In addition to the application form CD values increased with temperature (p < 
0.05; Figure 60). 
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Figure 60: Means and standard errors of the conjugated dienes of the yoghurt containing 
formulation wowCAPS
®
 and the fish oil analyzed according the treatment 
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The summary of CDs according to temperatureand UV treatment are shown in 
Table 19. 
 
Table 19: Conjugated dienes [%] of the formulation wowCAPS
®
 and the fish oil stored at 
different conditions 
Sample 
Average (n=4) 
[%] 
Standard Deviation 
(n=4) 
wowCAPS
®
 3-6°C 0.271 0.136 
wowCAPS
®
 30°C 0.576 0.119 
wowCAPS
®
 70°C 0.700 0.114 
wowCAPS
®
 UV 254 nm 0.531 0.092 
Fish oil 3-6°C 0.499 0.086 
Fish oil 30° 0.618 0.080 
Fish oil 70°C 1.781 0.064 
Fish oil UV 254 nm 0.634 0.082 
 
Figure 61: Conjugated dienes of the formulation wowCAPS
®
 and the fish oil stored at 
different conditions 
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These trials showed an increase of CD in the oils and formulations stored at 30 
°C and 70 °C and the oil and formulation treated with ultraviolett light at 254 nm 
wavelenght compared to the samples stored at 3-6 °C. 
As seen in Figure 62 CD values in fish oil are higher than in the wowCAPS® (p 
< 0.05). 
 
Figure 62: Means and standard errors of the conjugated dienes of the formulation 
wowCAPS
®
 and the fish oil 
 
As seen in Figure 63, CD values increased with temperature and are higher in 
the fish oil than in the wowCAPS® (p < 0.05). No significant difference was 
observed between the wowCAPS® and the fish oil after UV treatment at 254 nm 
(Figure 64). 
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Figure 63: Means and standard errors of the conjugated dienes of the formulation 
wowCAPS
®
 and the fish oil analyzed according to the storage temperature (T) 
 
 
Figure 64: Means and standard errors of the conjugated dienes of the formulation 
wowCAPS
®
 and the fish oil analyzed according UV irradiation 
 
The formulation has a protective effect against oxidation for the fish oil. 
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5.1.5.2 Conjugated trienes 
Storage of the yoghurt at 30 °C caused an increase in conjugated trienes (CT) 
compared with the yoghurt stored at 3-6 °C. The yoghurts were stored at these 
temperatures for 9 weeks. 
This was detected in the yoghurt enriched with the formulation wowCAPS® as 
well as in the yoghurt enriched with the fish oil. The CTs are higher in both 
samples of the yoghurt enriched with oil than in the yoghurt containing the 
formulation. 
Table 20: Conjugated trienes [%] of yoghurts containing formulation wowCAPS
®
 and fish oil 
Sample 
Average (n=4) 
[%] 
Standard Deviation 
(n=4) 
Yogurt containing wowCAPS
®
 3-6°C 0.001 0.001 
Yogurt containing wowCAPS
®
 30°C 0.122 0.100 
Yogurt containing fish oil 3-6°C 0.163 0.092 
Yogurt containing fish oil 30°C 0.329 0.108 
 
 
Figure 65: Conjugated triene values of yoghurts containing formulation wowCAPS
®
 and fish 
oil 
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As seen in Figure 66 below the application of the oil into the yoghurt showed an 
high impact on conjugated trienes. Conjugated trienes in the yoghurt containing 
formulation wowCAPS® are significantly lower that in the yoghurt containing fish 
oil (p < 0.05). 
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Figure 66: Means and standard errors of the conjugated trienes of the yogurt containing 
formulation wowCAPS
®
 and the fish oil 
 
In addition to the application form CT values increased with temperature (p < 
0.05; Figure 67). 
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Figure 67: Means and standard errors of the conjugated trienes of the yoghurt containing 
formulation wowCAPS
®
 and the fish oil analyzed according to the storage temperature 
The summary of CTs according to temperature and UV treatment are shown in 
Table 21. 
Table 21: Conjugated trienes [%] of the formulation wowCAPS
®
 and the fish oil stored at 
different conditions 
Sample 
Average (n=4) 
[%] 
Standard Deviation 
(n=4) 
wowCAPS
®
 3-6°C 0.050 0.077 
wowCAPS
®
 30°C 0.176 0.108 
wowCAPS
®
 70°C 0.292 0.095 
wowCAPS
®
 UV 254 nm 0.190 0.102 
Fish oil 3-6°C 0.349 0.094 
Fish oil 30° 0.813 0.082 
Fish oil 70°C 1.240 0.071 
Fish oil UV 254 nm 0.003 0.001 
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Figure 68: Conjugated trienes of the formulation wowCAPS
®
 and the fish oil stored at 
different conditions 
 
These trials showed an increase in CTs in the oils and formulations stored at 30 
°C but particularly at 70 °C and the oil and formulation treated with ultraviolett 
light at 254 nm wavelenght compared with the samples stored at 
3-6 °C. 
As seen in Figure 69 below the results considering the dosage form showed an 
high impact of the dosage form on the degree of CTs. One-Way ANOVA 
analysis showed a significant difference (p < 0.05) between conjugated trienes 
of wowCAPS® and fish oil. 
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Figure 69: Means and standard errors of the conjugated trienes of the formulation 
wowCAPS
®
 and the fish oil according the dosage form 
 
As seen in Figure 70, CD values increased with temperature and are higher in 
the fish oil than in the wowCAPS® (p < 0.05). 
 
Figure 70: Means and standard errors of the conjugated trienes of the formulation 
wowCAPS
®
 and the fish oil according to the storage temperature (T) 
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No significant difference was observed between the wowCAPS® and the fish oil 
after UV treatment at 254 nm (Figure 71). 
 
Figure 71: Means and standard errors of the conjugated trienes of the formulation 
wowCAPS
®
 and the fish oil according UV irradiation 
5.1.6 Fluorometric analysis – ORAC assay 
In Table 22 the trolox equivalent measured with the ORAC assay is shown for the 
yogurt containing wowCAPS® and fish oil. 
While the real quantity of antioxidants in the fish oil is not disclosed herein it 
affects both the test with free oil and with wowCAPS®. It is then reasonably not 
to consider the “baseline” antioxidant level of the pure fish oil  
The ORAC assay is traditionally conceived for measuring the oxidation 
properties of water soluble substances; however, it can be applied as well to 
hydrophobic substances when properly dispersed in the hydrophilic media in 
which the samples are being tested.  
The results are shown in Table 22. 
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Table 22: Trolox equivalent [μmol] of the yoghurt containing wowCAPS® and fish oil 
day 
Trolox equivalent of 
yoghurt containing 
wowCAPS
®
 
(average of 2 measurements) 
[μmol] 
Trolox equivalent of  
yoghurt containing 
fish oil 
(average of 2 measurements) 
[μmol] 
4 0.00165 0.00159 
6 0.00209 0.00196 
10 0.00239 0.00228 
13 0.00214 0.00210 
17 0.00228 0.00239 
20 0.00259 0.00256 
 
There is not a true independence of the values to apply a standard paired 
Student’s t-test (since the physical effect happening in one value still is present 
in the next one). Therefore the analysis has been done according the non-
parametric Paired-Sample Wilcoxon Signed Rank Test. At the level 0.05 the two 
distributions are not significantly different. 
Therefore, it is concluded that the ORAC test is not capable to detect the 
influence (in the yogurt food matrix) of the microencapsulation of the omega-3 in 
the product wowCAPS®.  
This does not necessarily mean that the microencapsulation has no effect on 
the oxidation / reduction properties of the yogurt, rather that if existent, they 
cannot be detected with the ORAC test. This result can be easily explained by 
the fact that the total influence of the omega-3 (and wowCAPS®) in the highly 
complex yogurt matrix, at the concentrations employed, is negligible. 
In Table 23 and Figure 72 the Trolox equivalent measured with the ORAC 
assay is shown for the formulation wowCAPS® and the fish oil. 
 
Table 23: Trolox equivalent [μmol] of the formulation wowCAPS® and the fish oil 
 
Trolox equivalent of 
formulation wowCAPS
® 
(average of 2 measurements) 
[μmol] 
Trolox equivalent of 
the fish oil 
(average of 2 measurements) 
[μmol] 
3-6 °C 0.00972 0.09137 
70 °C 0.00747 0.09647 
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Figure 72: Trolox equivalent [μmol] of wowCAPS
®
 and fish oil 
 
The result shown in the Table 23 and in Figure 72 reflects a behaviour 
previously observed at GAT Food Essentials GmbH. The free fish oil appears to 
provide an antioxidant effect in much higher degree than the wowCAPS®. 
However, this effect is believed to happen due to the faster oxidation of the 
PUFAs contained in the pure fish oil than that of fluorescein. 
We believe that what we observe is due to a temporary protective effect of the 
omega-3 over fluorescein. Taking this into account the wowCAPS® formulation 
effects a remarkable isolation against oxidation.  
 
5.2 Sensory evaluation 
5.2.1 Yoghurt 
The sensory evaluation was carried out once a week for 6 weeks with 8 
participants. The values for taste and smell were counted together as off-flavor 
against the general impact of each sample. Then the averages of the 8 
panelists of each tasting were compared.  
There were no significant differences in between the panelists. 
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In Table 24 and Figure 73 (yogurt enriched with wowCAPS®) as well as in 
Table 25 and Figure 74 (yogurt enriched with fish oil) the outcomes of the 
tastings over the 6 weeks storage are shown. 
Table 24: Outcome tasting of yoghurt enriched with wowCAPS
®
 
 
off-flavor [points] general impact [points] 
initial 7.8 ± 0.4 7.8 ± 0.4 
week 1 7.7 ± 0.4 7.3 ± 0.7 
week 2 7.3 ± 0.6 7.5 ± 0.4 
week 3 7.5 ± 0.4 7.7 ± 0.3 
week 4 7.3 ± 0.6 7.6 ± 0.4 
week 5 7.3 ± 0.6 7.8 ± 0.3 
 
 
Figure 73: Outcome tasting of yoghurt enriched with wowCAPS
®
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One-Way ANOVA analysis on the off-flavor shows that there are no significant 
differences in between the off-flavor tested at any time when the oil is 
incorporated in the yogurt in the form of wowCAPS®. 
Table 25: Outcome tasting of yoghurt enriched with fish oil 
 
off-flavor [points] general impact [points] 
initial 7.0 ± 0.6 7.0 ± 0.4 
week 1 6.8 ± 0.4 6.7 ± 0.6 
week 2 7.1 ± 0.3 6.6 ± 0.3 
week 3 6.9 ± 0.5 7.0 ± 0.4 
week 4 6.6 ± 0.4 6.5 ± 0.4 
week 5 6.3 ± 0.4 6.2 ± 0.3 
 
 
Figure 74: Outcome tasting of yoghurt enriched with fish oil 
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One-Way ANOVA analysis on the off-flavor shows that there are significant 
differences in between the initial value or the week 2 value and the week 5 
(p < 0.05) when the oil is incorporated in pure form. 
 
There was no significant difference in the off flavor of the yoghurt containing 
wowCAPS®. Over the storage time it gained better results than the yoghurt 
containing fish oil, which showed a significant difference in the terms of off-
flavor over time. Nevertheless it is to mention that also the yoghurt containing 
fish oil remained in the accepted area throughout the evaluation time. Although 
the statistical results are definitive due to the limited resources for extended 
tests, it can be made the reasonable assumption that the enrichment with 
wowCAPS® is more suitable for yogurt than the enrichment with pure fish oil. 
 
5.2.2 Cauliflower soup 
The cauliflower soup was cooked and tasted immediately afterwards. For the 
tasting after 7 days it was heated in the microwave. No fishy or off-taste or smell 
could be detected in the cauliflower soup enriched with wowCAPS®. Each 
tasting was performed with 6 panelists. As these tastings were performed to test 
the acceptance of the cauliflower soup enriched with wowCAPS® there were no 
control samples for comparison. The values for taste and smell were counted 
together as off-flavor against the general impact of each sample. Then the 
mean values of the 6 panelists of the two tastings were compared. 
The outcome of the tastings is shown in Table 26 and Figure 75. 
Table 26: Outcome tasting of cauliflower soup enriched with wowCAPS
®
 
 
off-flavor [points] general impact [points] 
initial 7.8 ± 0.3 7.8 ± 0.3 
week 1 7.6 ± 0.3 7.5 ± 0.3 
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Figure 75: Outcome tasting of cauliflower soup enriched with wowCAPS
® 
 
There were no significant differences between initial levels and levela after 7 
days. From this can be concluded that the food matrix cauliflower soup could be 
suitable for the enrichment with wowCAPS®. 
 
5.2.3 Tomato sauce 
The tomato sauce was tasted plain. For the tasting after 7 days it was heated in 
the microwave. No fishy or off-taste or smell could be detected in the tomato 
sauce enriched with wowCAPS®. Each tasting was performed with 8 panelists. 
As these tastings were performed to test the acceptance of the tomato sauce 
enriched with wowCAPS® there were no control samples for comparison. The 
values for taste and smell were counted together as off-flavor against the 
general impact of each sample. Then the mean values of the 8 panelists of the 
two tastings were compared. 
The outcome of the tastings is shown in Table 27and Figure 76. 
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Table 27: Outcome tasting of tomato sauce enriched with wowCAPS
®
 
 
off-flavor [points] general impact [points] 
initial 7.6 ± 0.3 7.5 ± 0.4 
week 1 7.5 ± 0.4 7.1 ± 0.3 
 
 
Figure 76: Outcome tasting of tomato sauce enriched with wowCAPS
® 
 
There were no significant differences between initial levels and levels after 7 
days. From this it can be concluded that the food matrix tomato sauce could be 
suitable for the enrichment with wowCAPS®. 
 
5.2.4 UHT milk 
No fishy flavor could be detected in the UHT milk enriched with wowCAPS® in a 
descriptive tasting with 8 panelists. 
As these tastings were performed to test the acceptance of the UHT milk 
enriched with wowCAPS® the panelists didn’t get any control samples for 
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comparison. The values for taste and smell were counted together as off-flavor 
against the general impact of each sample. Then the mean values of the 8 
panelists of each tasting were compared. 
The outcome of the 3 tastings throughout the storage time is shown in Table 28 
and Figure 77. 
Table 28: Outcome tasting of UHT milk enriched with wowCAPS
®
 
 
off-flavor [points] general impact [points] 
initial 7.8 ± 0.2 6.9 ± 0.4 
1 month 7.7 ± 0.3 6.8 ± 0.2 
3 months 7.9 ± 0.2 6.7 ± 0.4 
 
 
Figure 77: Outcome tasting of UHT milk enriched with wowCAPS
®
 
 
There were no significant differences between initial levels and levels after 3 
months. From this it can be concluded that the food matrix UHT milk could be 
suitable for the enrichment with wowCAPS®. 
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5.3 Microscopic observation 
5.3.1 Formulation wowCAPS® 
Figure 78 shows a picture of the microscopic observation of the formulation 
wowCAPS® in four hundredfold magnification. The picture shows intact 
capsules in different sizes 
 
Figure 78: Microscopic observation of the formulation wowCAPS
®
, 1:400 magnification 
 
Figure 79 shows a picture of the microscopic observation of the formulation 
wowCAPS® in thousand fold magnification. The picture shows intact capsules in 
different sizes. 
 
Figure 79: Microscopic observation of the formulation wowCAPS
®
, 1:1000 magnification 
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5.3.2 Yoghurt 
5.3.2.1 Yoghurt containing wowCAPS® 
Figure 80 shows a picture of the microscopic observation of the yoghurt 
containing wowCAPS® on the day of the initial analysis in hundredfold 
magnification. Capsules are small and well distributed and marked with a red 
ring. 
 
Figure 80: Microscopic observation of the yoghurt containing wowCAPS
®
, 1:100 
magnification 
 
Figure 81 shows a picture of the microscopic observation of the yoghurt 
containing wowCAPS® on the day of the initial analysis in four hundredfold 
magnification. Capsules are small and well distributed and marked with a red 
ring. 
116 
 
 
Figure 81: Microscopic observation of the yoghurt containing wowCAPS
®
, 1:400 
magnification 
 
Figure 82 shows a picture of the microscopic observation of the yoghurt 
containing wowCAPS® on the day of the initial analysis in thousand fold 
magnification. Capsules are small and well distributed and marked with a red 
ring. 
 
Figure 82: Microscopic observation of the yoghurt containing wowCAPS
®
, initially, 1:1000 
magnification 
 
Figure 83 shows a picture of the microscopic observation of the yoghurt 
containing wowCAPS® after 21 days of storage at 3-6 °C in thousand fold 
magnification. Capsules are small and well distributed and marked with a red 
ring. 
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Figure 83: Microscopic observation of the yoghurt containing wowCAPS
®
, 21 days at 3-6 
°C, 1:1000 magnification 
 
From these pictures can be concluded that the microcapsules remain stable 
during the production process of yogurt and are not affected by the yogurt 
starter cultures. 
5.3.2.2 Yoghurt containing fish oil 
Figure 84 shows a picture of the microscopic observation of the yoghurt 
containing fish oil on the day of the initial analysis in hundredfold magnification. 
Oil droplets are clearly visible and marked with a blue ring. 
 
Figure 84: Microscopic observation of the yoghurt containing fish oil, 1:100 magnification 
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Figure 85 shows a picture of the microscopic observation of the yoghurt 
containing fish oil on the day of the initial analysis in four hundredfold 
magnification. Oil droplets are clearly visible and marked with a blue ring. 
 
Figure 85: Microscopic observation of the yoghurt containing fish oil, 1:400 magnification 
 
Figure 86 shows a picture of the microscopic observation of the yoghurt 
containing fish oil on the day of the initial analysis in thousand fold 
magnification. Oil droplets are clearly visible and marked with a blue ring. 
 
Figure 86: Microscopic observation of the yoghurt containing fish oil, initially, 1:1000 
magnification 
 
Figure 87 shows a picture of the microscopic observation of the yoghurt 
containing fish oil after 21 days of storage at 3-6 °C in thousand fold 
magnification. Oil droplets are clearly visible and marked with a blue ring. 
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Figure 87: Microscopic observation of the yoghurt containing fish oil, 21 days at 3-6 °C, 
1:1000 magnification 
 
5.3.3 Cauliflower soup 
Figure 88 shows a picture of the microscopic observation of cauliflower soup 
containing wowCAPS® in four hundredfold magnification. The picture shows 
intact capsules in different sizes. Some capsules are marked with a red ring for 
better detection. 
 
 
Figure 88: Microscopic observation of the cauliflower soup containing wowCAPS
®
, 1:400 
magnification 
 
Figure 89 shows a picture of the microscopic observation of cauliflower soup 
containing wowCAPS® in thousand fold magnification. The picture shows intact 
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capsules in different sizes. Some capsules are marked with a red ring for better 
detection. 
 
Figure 89: Microscopic observation of the cauliflower soup containing wowCAPS
®
, 1:1000 
magnification 
 
From these pictures can be concluded that the microcapsules remain stable 
during the production process of cauliflower soup. 
 
5.3.4 Tomato sauce 
Figure 90 shows a picture of the microscopic observation of tomato sauce 
containing wowCAPS® in four hundredfold magnification. The picture shows 
intact and well distributed capsules in different sizes. Some capsules are 
marked with a red ring for better detection 
 
Figure 90: Microscopic observation of the tomato sauce containing wowCAPS
®
, 1:400 
magnification 
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Figure 91 shows a picture of the microscopic observation of tomato sauce 
containing wowCAPS® in thousand fold magnification. The picture shows intact 
and well distributed capsules in different sizes. Some capsules are marked with 
a red ring for better detection. 
 
Figure 91: Microscopic observation of the tomato sauce containing wowCAPS
®
, 1:1000 
magnification 
 
From these pictures can be concluded that the microcapsules remain stable 
during the production process of tomato sauce. 
 
5.3.5 UHT milk 
Figure 92 shows a picture of the microscopic observation of the UHT milk 
enriched with wowCAPS® at the time point of the initial analysis in four 
hundredfold magnification. The picture shows intact and well distributed 
capsules in different sizes. In the background the milk micelles are visible. 
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Figure 92: Microscopic observation of the UHT milk enriched with wowCAPS
®
, initially, RT, 
1:400 magnification 
 
Figure 93 shows a picture of the microscopic observation of the UHT milk 
enriched with wowCAPS® at the time point of initial analysis in thousand fold 
magnifictation. The picture shows intact and well distributed capsules in 
different sizes. In the background the milk micelles are visible. 
 
Figure 93: Microscopic observation of the UHT milk enriched with wowCAPS
®
, initially, RT, 
1:1000 magnification 
 
Figure 94 shows a picture of the microscopic observation of the UHT milk 
enriched with wowCAPS® after 3 months storage at room temperature in four 
hundredfold magnification. The picture shows intact and well distributed 
capsules in different sizes. In the background the milk micelles are visible. 
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Figure 94: Microscopic observation of the UHT milk enriched with wowCAPS
®
, 3 months, 
RT, 1:400 magnification 
 
Figure 95 shows a picture of the microscopic observation of the UHT milk 
enriched with wowCAPS® after 3 months storage at room temperature in 
thousand fold magnifictation. The picture shows intact and well distributed 
capsules in different sizes. In the background the milk micelles are visible. 
 
Figure 95: Microscopic observation of the UHT milk enriched with wowCAPS
®
, 3 months, 
RT, 1:1000 magnification 
 
From these pictures can be concluded that the microcapsules remain stable 
during the production process of UHT milk. 
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6. SUMMARY 
This study addresses how the microencapsulation of oils enriched with omega-3 
fatty acids helps to improve their stability when incorporated into foods. 
The current available literature is limited regarding a precise methodology for 
the analysis and interpretation of data when analyzing functional foods with 
microencapsulated omega-3 fatty acids. 
In order to assess the stability of microencapsulated omega-3 in foods, 
detection methods for the omega-3’s enriched oils, for the concentrated 
formulation containing them (the formulation to be mixed with the food) and for 
the final food containing such microcapsules have been developed in this study. 
The oil used for this purpose was from the fish species Gadus morhua origin, 
with a content of EPA and DHA of approx. 26w%. The formulation object of this 
study has been the proprietary product wowCAPS® (with a content in EPA and 
DHA of ca. 7w%) owned by GAT Food Essentials GmbH. The foods selected 
for this work was yogurt, cauliflower soup, tomato sauce and UHT milk, 
enriched at different levels with either the fish oil mentioned above or with the 
wowCAPS® product. 
The well-established tests in use to determine the oil quality such as peroxide 
value, acid value, p-anisidine value, 2-thiobarbituric acid value, levels of 
conjugated dienes have their limitations in the assessment of the quality of 
foods enriched with omega-3 from fish oil. Notably, these methods fail as well 
as the method to evaluation whether omega-3 are of microbial or vegetable 
origin. Therefore additional analysis have been employed to come closer to a 
less subjective evaluation of the quality of omega-3 fatty acids in the context of 
functional foods.  
Contrary to what would have been expected, plain analysis of total amount of 
omega-3 fatty acids by means of HPLC or GC is unable to detect the small 
degree of decomposition of omega-3 (that is in turn enough for providing 
unacceptable organoleptic characteristics) when they are incorporated in 
complex food matrices.  
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Notably, the analytical method to assess the omega-3 fatty acids used in the 
experimental part has shown to be precise and specific enough for a correct 
determination of the most important omega-3 from an industrial point of view, 
namely EPA and DHA. The content of EPA and DHA in the final products is 
usually what is reflected in the functional label as the claimed content of omega-
3. Therefore, although the method shows not to be valid for all fatty acids 
analyzed, it is still of full applicability for industrial purposes, and for the purpose 
of the present work. 
When also considering the other results (e.g., peroxide values, ORAC tests and 
most importantly, the organoleptic panel tasting), it could be considered that 
there is an effective protection of the wowCAPS® formulation. 
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7. ZUSAMMENFASSUNG 
Ziel dieser Diplomarbeit war festzustellen wie die Mikroverkapselung die 
Stabilität von omega-3 Fettsäuren in angereicherten Lebensmitteln verbessert. 
In der vorhandenen Literatur finden sich wenig präzise Methoden für die 
Analyse und Auswertung von Functional Foods, die mit mikroverkapselten 
omega-3 Fettsäuren angereichert wurden. 
Um die Stabilität von mikroverkapselten omega-3 Fettsäuren in Lebensmitteln 
beurteilen zu können wurden in dieser Arbeit Analysemethoden entwickelt, die 
sowohl für das omega-3 reiche Öl, die konzentrierte Formulierung als auch für 
die angereicherten Lebensmittel anwendbar sind. Das verwendete Öl wurde 
ausschließlich aus der Fischspezies Gadus morhua gewonnen und hat einen 
Gehalt an EPA/DHA von 26%w. Die in dieser Arbeit verwendete 
Mikroverkapselung wowCAPS®, mit einem Gehalt an EPA und DHA von ca. 
7%w, ist Eigentum der Firma GAT Food Essentials GmbH. Die verwendeten 
Lebensmittel Jogurt, Karfiolsuppe, Tomatensauce und UHT-Milch wurden mit 
unterschiedlichen Konzentrationen an Fischöl bzw. dem Produkt wowCAPS® 
angereichert. 
Die gängigen Tests zur Evaluierung der Ölqualität, wie zum Beispiel 
Peroxidzahl, Säurezahl, p-Anisidinzahl, Thiobarbitursäuretest, Menge an 
konjugierten Dienen, sind für die Analyse mit omega-3 angereicherter 
Lebensmittel nur bedingt anwendbar. Auch für die Evaluierung von omega-3 
Fettsäuren tierischer oder mikrobieller Herkunft sind diese Methoden nicht 
unbedingt geeignet. Aus diesem Grund wurden weitere Analysen durchgeführt 
um eine weniger subjektive Evaluierung der Qualität von omega-3 Fettsäuren in 
Functional Foods zu erreichen. 
Im Gegensatz zu den Erwartungen war es weder mittels HPLC- noch mittels 
GC-Analyse möglich den geringen Grad des Abbaus der omega-3 Fettsäuren 
im Lebensmittel zu detektieren obwohl dieser bereits in geringem Maße die 
organolpetischen Eigenschaften beeinträchtigt. 
Die Methode zur Analyse der omega-3 Fettsäuren, die im experimentellen Teil 
verwendet wurde, hat gezeigt, dass sie präzise und spezifisch genug ist um die 
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omega-3 Fettsäuren zu detektieren, die in der Industrie am wichtigsten sind, 
EPA und DHA. Der Gehalt an EPA und DHA ist in den meisten Fällen auf den 
Etiketten der angereicherten Lebensmittel ausgewiesen. Daher ist die Methode, 
obwohl sie nicht für alle analysierten Fettsäuren gültig zu sein scheint, sehr 
wohl geeignet für industrielle Zwecke und die Zwecke dieser Arbeit. 
Im Hinblick auf die Resultate der weiteren Analysen (z.B. Peroxidezahl, ORAC-
Tests und sensorische Tests), kann auf einen effektiven Schutz durch die 
wowCAPS®-Formulierung geschlossen werden. 
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9. APPENDIX 
9.1 Evaluation sheet for sensory evaluation 
Figure 96: Evaluation sheet for sensory evaluation 
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